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HIV-1 is a virus with a very variable genome and therefore has the ability to 
adapt to new environments which include escape from immune pressure and 
suboptimal antiretroviral treatment. Next-generation sequencing (NGS), especially 
ultra-deep pyrosequencing (UDPS), has enabled in-depth sequencing studies with a 
previously unattainable resolution. However, the technology is more error prone than 
traditional sequencing which makes it challenging to interpret UDPS results. In this 
thesis we carried out comprehensive work to identify, characterize and reduce errors as 
well as investigate the UDPS performance (Papers II, III and IV). In Papers IV and V 
we used UDPS to study HIV-1 minority variants. Novel primer design software was 
developed in Paper I and a new method to tag molecules was developed and evaluated 
in Paper VI. The design of primers is of special importance in NGS to avoid selective 
amplification which may skew estimates of variant frequencies. We developed a 
computer program, PrimerDesign, to meet the changed requirements for primer design. 
PrimerDesign is tailored to design primers from a multiple alignment and is suitable for 
all types of NGS that is preceded by amplification. The new Primer ID methodology 
has the potential to provide highly accurate deep sequencing. We identified three major 
challenges; a skewed resampling of Primer IDs, low recovery of templates and 
erroneous consensus sequences. Undetected this would lead to an underestimation in 
diversity of the quasispecies and cause a skewed and incorrect results. As many of our 
other findings, the methodology is not limited to HIV or virology.  
The resolution of UDPS analysis is primarily determined by the number of input 
DNA templates, the error frequency of the method and the efficiency of data cleaning. 
In Papers II and IV we therefore optimized the pre-UDPS protocol and investigated 
the characteristics and sources of errors that occurred when UDPS was used to 
sequence a fragment of the HIV-1 pol gene. UDPS introduced indel errors located in 
homopolymeric regions that were removed by our in-house data cleaning software. The 
remaining errors were primarily substitution errors that were introduced in the PCR that 
preceded UDPS. Transitions were significantly more frequent than transversions, which 
will limit detection of minor variants and mutations in HIV-1 as well as other species. 
Further, we evaluated the quality and reproducibility of the UDPS technology in 
analysis of the same pol gene fragment. We concluded that the UDPS repeatability was 
good for both major and minor variants. In our experimental settings, in vitro 
recombination and sequencing directions posed a minor problem, but still needs to be 
considered especially for studies of minor viral variants and linkage between mutations.  
Minority resistance mutations have been shown to impact the clinical outcome in 
treated patients. We examined the presence of pre-existing drug resistance mutations in 
treatment-naïve HIV-1 infected individuals and found very low levels of M184I, 
T215A and T215I, but no presence of M184V, Y181C, Y188C or T215Y/F. This 
indicates that the natural occurrence of these mutations is very low. When the same 
individuals experienced treatment failure or interruption, almost 100 % of the wild-type 
virus respective drug resistance variants were replaced. Other patients were followed 
from primary HIV infection (PHI) until their virus switched coreceptor use from CCR5 
(R5) to CXCR4 (X4). We did not find any X4-using virus present as a minority 
population during PHI. The results indicate that the X4-using population most probably 
evolved in stepwise fashion from the R5-using populations in each of the three patients. 
In conclusion, we have developed and used new NGS and bioinformatic methods 
to study HIV-1 genetic variation. We have shown that UDPS can be used to gain new 
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1 INTRODUCTION 
 
1.1 HUMAN IMMUNODEFICIENCY VIRUS 
1.1.1 History 
In 1981 came the first alarming reports of young men experiencing unusual 
opportunistic infections and rare malignancies [1] [2]. Over three decades has now 
passed since these first reports. The causative agent leading to acquired 
immunodeficiency syndrome (AIDS) has been found [3-5] and is referred to as human 
immunodeficiency virus (HIV). The virus is globally spread and has to date infected in 
excess of 60 million individuals and caused over 25 million deaths. The pandemic and 
the disease is far from over and more than 35 million people are living with HIV 
infection today [6], 
 
1.1.2 Origin and classification 
AIDS is in fact caused by two viruses, HIV type 1 (HIV-1) and HIV type 2 (HIV-2). 
These are morphologically similar but genetically and antigenically distinct [7]. HIV-1 
is much more widespread, more infectious and causes a faster progression to AIDS 
than HIV-2 [8, 9]. This thesis is primarily focused on HIV-1. HIV-1 is a part of the 
lentivirus genus and belongs to the Retroviridae family. It comprises four distinct 
lineages, termed groups (M) (main), N (non-M-non-O), O (Outlier), and P. Each group 
is the result of an independent cross-species transmission event of simian 
immunodeficiency viruses (SIVs) [7]. SIVs are naturally infecting African primates 
[10]. Group M originates from SIVcpz, a virus that infects two of four subspecies of 
chimpanzees. Group M is by far the most prevalent group and completely dominates 
the global pandemic. The transmission event that founded the M group is estimated to 
have occurred in southeastern Cameroon around 1910 [11]. As Group M spread, time 
and geographical dispersal caused the virus to evolve into different lineages. Group M 
is therefore divided into nine pure subtypes (A, B, C, D, F, G, H, J and K) and many 
(currently 58 known) circulating recombinant forms (CRFs) [12, 13]. Groups N, O and 
P represent less than 1 % of the infections and are very regionally located [14-18]. The 
same is true for HIV-2. 
 
1.1.3 The current HIV epidemic 
According to WHO´s and UNAIDS´ estimations, between 32.2 and 38.8 million 
individuals were living with HIV infections in 2012. In 2012, 2.3 million individuals 
became infected by HIV and 1.6 million individuals died due to AIDS. The infection is 
not evenly distributed over the world. In Sub-Saharan Africa, 25 million individuals are 
estimated to live with HIV and in some countries like Botswana and Swaziland the 








Figure 1. Adults and children estimated to be living with HIV globally in 2012. 
Adapted from [6]. 
 
In 1983, the first known HIV-infection in Sweden was reported. Until June 2013, 
approximately 10,500 individuals have been diagnosed with the infection [19]. At that 
time approximately 6,200 HIV infected individuals were known to be living in Sweden, 
which corresponds to a prevalence of 0.06 %. In 2012, 441 new infections were 
reported. This corresponds roughly to the average incidence of newly infected patients 
per year in the preceding decade. The majority of infections (51 %) were heterosexual 
acquired and 70 % stated that they had been infected abroad [20]. Of patients infected 
abroad, 79 % were born abroad and infected prior to the first arrival to Sweden. Of the 
117 domestic transmissions, 56 % occurred between men who have sex with men 
(MSM). The number of MSM transmissions has increased significant since 2003 [20].  
 
1.2 HIV-1 VIROLOGY 
1.2.1 Structure, genes and regulatory enzymes 
The HIV-1 particle is enveloped, spherical with a diameter of approximately 120 nm. 
The envelope is obtained when the virus buds from the host cell and consists of a lipid 
layer derived from the cell membrane and viral trimeric transmembrane glycoprotein 
(gp41) linked to the outer trimeric glycoprotein (gp120). The viral envelope surrounds 
the nucleocapsid, which contains the viral enzymes: reverse transcription (RT), 
protease (PR) and integrase (IN), as well as two positive sensed single stranded RNA 
molecules (ssRNA). Each of the RNA strands consists of approximately 9,700 bases. 
 
 
Figure 2. Schematic structure of the HIV-1 virion. 
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Like all retroviruses, the HIV genome contains the gag, env and pol genes. They 
encode the major structural and enzymatic proteins; group specific antigen (Gag), 
polymerase (Pol), and envelope (Env). The gag-gene encodes the capsid proteins. The 
Gag precursor is the p55 protein which is processed to p17 (matrix), p24 (capsid), p7 
(nucleocapsid), and p6 proteins, by the viral protease. The genomic region of pol 
encodes the viral enzymes RT, PR and IN. The env-gene encodes the polyprotein which 
is cleaved into the outer gp120 and the transmembrane gp41. The genome also codes 




Figure 3. The genome organization of HIV-1 
 
 
1.2.2 Replication  
The HIV-1 replication cycle begins with the virus attaching to the target cell via 
binding of the virus envelope protein gp120 to the primary cellular receptor, the CD4 
protein [21, 22]. CD4 is found on CD4+ T-lymphocytes (CD4 cells), macrophages, 
monocytes, dendritic cells and brain microglia. The envelope protein binding induces a 
conformational change allowing the envelope to bind to a coreceptor, which is either of 
the chemokine receptors CCR5 (R5-using virus) or CXCR4 (X4-using virus). Some 
viruses, however, use both coreceptors (R5X4-using or dual tropic virus) [23] (more on 
this in section 1.4.2). Thereafter, fusion of the host membrane and the viral envelope is 
mediated by a second conformational change which is unlocked by the coreceptor 
binding whereby the viral nucleocapsid is delivered into the host cell cytoplasm [24]. 
 
Following the host cell’s reception of the viral contents, the capsid is partially opened 
and the enzyme RT starts the reverse transcription of one ssRNA strand and generates a 
cDNA strand with its reverse transcription activity. The RNase H activity of the RT 
degrades the viral RNA template at the same time. Both RNA strands are needed to 
complete the cDNA synthesis, in part because the long terminal repeats (LTRs) at both 
ends of the genome are extended. Genetic variability in form of mutations occurs 
during the reverse transcription since the RT enzyme is error prone and lacks a proof 
reading mechanism. Another factor that contributes to the genetic variability is RT’s 
ability to switch between the two RNA strands which create a hybrid cDNA strand if 
the virus particle contains two genetically distinct RNA molecules as a result of dual 
infection of the cell from which the virus was produced. A complementary DNA strand 
is synthesized by the DNA polymerase activity of RT. A pre-integration complex 
termed PIC is created and transports the dsDNA molecule into the nucleus where IN 
catalyzes the integration of the viral genome into the host genome. At this stage of the 
process, the viral DNA genome is referred to as a provirus which can either directly 
continue the replication cycle or (much more rarely) enter a latent stage. In case the 
provirus stays active, the next step is transcription performed by the RNA polymerase 
II of the host cell. The first viral transcript is a full length RNA copy which is spliced 
into small mRNAs and translated to the early viral proteins Nef, Tat and Rev. Tat 
interacts with the transactivation response element (TAR) in 5’-end of the HIV mRNA 
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to promote efficient viral mRNA elongation. Rev binds to the rev responsible element 
(RRE) in the env-region of the viral mRNA, which induces a switch from synthesis of 
early to late viral proteins by promoting transport of unspliced and partially spliced 
RNA from the nucleus into the cytoplasm.  
  
The late transcription involves production of longer mRNAs by alternative splicing. 
The proteins Gag, Gag-Pol, Env, Vif, Vpr and Vpu are transcribed together with full-
length mRNA. All mRNAs are translated by the cellular host translation processes in 
the cytoplasm. The assembly of the components of new virus particles, i.e. structural 
proteins, viral enzymes and genomic RNA, takes place at the cellular membrane. The 
new viruses then bud from the cell taking a part of the host cell’s lipid layer with it to 
form the envelope. When the immature virus particle has left the cell, it matures after 
PR cleaves the Gag and Gag-Pol polyproteins into functional proteins forming the 
matrix, capsid and nucleocapsid proteins (Gag) as well as the viral enzymes (Gag-Pol). 
Following these last steps, the virus is ready to infect new cells. 
 
1.2.3 Genetic variability 
HIV-1 displays very high genetic variability and is ranked one of the most rapidly 
evolving organisms known [25]. The genetic diversity found at a single time point in a 
single infected individual exceeds the global variation in influenza isolates in an entire 
season [26]. This enormous variation allows the virus to evolve and escape both the 
immune pressure and suboptimal antiretroviral therapy. The genetic viral variants 
constituting the populations are called haplotypes, and these haplotypes form a viral 
quasispecies [27-29]. Several factors contribute to this effect, for example a high turn-
over rate, the error-prone reverse transcriptase and high potential for recombination. 
 
In the chronic stage of infection, in an untreated individual, one ml of plasma contains 
on average 104-105 or more HIV-particles. The generation time is short (the average 
replication time is ~1-2 days [30]) and the production rate of new virions is high which 
results in the production of approximately 1010 new virions per day in patients who are 
not receiving antiretroviral therapy (ART) [31-33]. 
 
Single nucleotide substitutions (point mutations) are spontaneously generated as the 
virus replicates. These are primarily caused by the error-prone reverse transcription 
process. Mutations also occur when the DNA is transcribed by the host RNA 
polymerase II and when G-to-A mutations are mediated by the cellular antiretroviral 
enzyme APOBEC3G (or APOBEC3F). There is no consensus on the relative 
contribution of these processes, but together they generate an average of 3.4 ×10−5 
mutations per nucleotide synthesized [34-37]. Since the HIV-1 genome is 
approximately 10,000 nucleotides long, this means that every third newly synthesized 
HIV genome contains a point mutation. Furthermore, the combination of the high 
mutation rate and the high virus production rate means that every possible single point 
mutation in the HIV genome arises spontaneously many times every day. These point 
mutations occur more or less randomly [38], but with a transition vs. transversion bias. 
G-to-A transitions are especially common, possibly as a result of APOBEC editing. 
Insertions and deletions (indels) of one or several nucleotides are also created during 
reverse transcription and contribute to the genetic variation [39]. Finally, recombination 
is a third source of genetic variation. Recombination arises because the RT enzyme 
switches between the two ssRNA molecules in the virus particle when the DNA copy is 
created in the newly infected cell. Thus, the DNA copy will always be a recombinant, 
but this usually has little consequence because the two RNA molecules in the incoming 
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virus particle usually are nearly identical. However, if two genetically distinct HIV 
variants infect the same cell, the viruses that are produced from this cell may be 
“heterozygous”, i.e. contain two genetically distinct RNA copies. If such a virus infects 
a new cell the DNA copy will be a mosaic with bits from both RNA variants. The 
effective recombination rate (e.g. the creation of genetically distinct variant) has been 
estimated to 1.4 ×10−5 recombination per site and generation [40]. 
 
New viral variants that arise through point mutations, indels and recombination are 
continuously screened for their fitness. There exist several different definitions of viral 
fitness, but here I refer to fitness as the virus ability to produce progeny, which depends 
on the ability of the virus to perform all steps in the replication cycle as well as the 
ability to adapt to the surrounding environment such as challenges posed by the 
immune system of the host and ART. The process by which mutations are maintained 
to the next replication cycle, and eventually becomes fixed, is a combination of 
selection and chance. Viral variants that carry advantageous mutations, i.e. mutations 
that increase virus fitness, will tend to increase in frequency. This is referred to as 
positive or Darwinian selection. The frequency of variants with disadvantageous 
mutations will tend to decrease and some mutations may even be directly lethal. This is 
referred to as negative or purifying selection. Neutral mutations will either become 
fixed or disappear depending on chance. However, chance will also affect the fate of 
moderately advantageous and disadvantageous mutations as described by Kimura in his 
model of neutral evolution [41].  
 
1.3 HIV-1 INFECTION  
1.3.1 Pathogenesis 
The clinical stages of the infection can be monitored through clinical symptoms and the 
levels of CD4 cells and virus particles in the blood as well as through many other 
clinical, immunological and viral markers.  
 
The period after the virus has been transmitted and the infection has been established is 
referred to as the eclipse period. The eclipse period lasts until the virus can be detected 
in blood which usually takes 7-21 days. During the eclipse period, the infected 
individual is asymptomatic and the virus spreads from the initial sites of replication in 
mucosa and local lymphatic tissue to other replication sites, primarily lymphatic tissue 
throughout the body. 
  
About 50 -70 % of the infected individuals experience clinical manifestations in the 
acute phase [42]. The phase is also referred to as primary HIV infection (PHI) (~2-4 
weeks). Symptomatic patients suffer from a flulike illness characterized by fever, sore 
throat, lymphadenopathy and rash [43]. Once the virus becomes detectable in blood 
plasma, it increases exponentially reaching 107 or more copies of viral RNA/ml blood 
[44]. The high level is a result from absence of the early immune response and rapid 
replication in gut-associated lymphoid tissue (GALT) and peripheral lymphoid tissue 
compartments [45-48]. The CD4 cells temporary decline in blood but partially recover 
following a rapid decline of plasma RNA levels and the emergence of immune 
response fighting the infection [30, 49]. Fiebig and colleagues has classified the acute 





Figure 4. Typical course of HIV infection. Patterns of CD4+ T-cell decline and virus 
load increase vary greatly between individuals. 
   
 
The chronic phase (~1 - 20 years) of HIV is usually asymptomatic for the infected 
individual. During the chronic phase, the virus levels in plasma reaches a semi-steady 
state (the viral set-point) well below the levels during its peak in the acute phase 
(usually 1,000 - 100,000 RNA copies/µl). The plasma HIV RNA levels remain constant 
or slowly increasing whereas the CD4 cells slowly decrease [30].  
 
AIDS is the end stage of the HIV infection and develops when the CD4 cells have 
declined so that immune system cannot control the HIV infection as well as other 
(opportunistic) infections and tumors. This occurs when CD4 counts have decreased to 
levels below 200 cells/µl, but it is not uncommon that early symptoms of 
immunodeficiency may appear already when CD4 counts are 200 - 500 cells/µl. During 
the AIDS stage, viremia steadily rises whilst the CD4 cell counts continue to decline. 
The infected individual may experience unusual opportunistic infections like 
pneumocystis jirovecii pneumonia, esophageal candidiasis and brain toxoplasmosis 
and/or rare malignancies like Kaposi´s sarcoma and Burkitt’s lymphoma. The 
development from HIV-infection to AIDS takes on average 10 years [51] but varies 
between individuals. 
 
There are infected individuals who can control the infection and remain asymptomatic 
despite the absence of ART. The virus is undetectable using standard assays but single 
viruses can be detected with special assays. These individuals are called long term non-
progressors or elite controllers. The definitions of these two groups partly overlap but 
elite controllers are superior in controlling the infection.  
 
1.3.2 Transmission 
In 2012, 2.3 million new cases of HIV infection were estimated to have occurred 
globally [6]. HIV can be transmitted by sexual encounter (unprotected vaginal, anal and 
oral intercourse), but can also be vertically transmitted from mother to child or via 
contaminated blood or needles. Heterosexual transmission accounts for nearly 70 % of 
the new cases of HIV-1 infection worldwide [6]. 
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In the absence of ART, the risk rate of penile-vaginal transmission of HIV-1 has been 
estimated between 1 in 2000 and 1 in 200. The probability for HIV transmission of 
unprotected anal intercourse is higher and range between 1 in 300 and 1 in 20 [49, 52-
55]. The risk of HIV transmission is influenced by many factors. One of them is the 
viral load of the transmitting partner. A study in HIV-1 discordant couples has shown a 
2.5-fold increase in transmission for every 10-fold increase observed in viral load [56, 
57]. The clinical stage of infection in the transmitting partner is another factor. The risk 
of infection being transmitted from an individual with acute or early infection is higher 
than from one with an established infection due to the very high virus levels during this 
stage of the disease, but also because the infected person usually is unaware of his/her 
infection. In addition, co-infections may influence the risk rate, particularly infections 
causing genital inflammation ulcers in the genital tract [58]. The transmission event of 
HIV-1 involves a genetic bottleneck where one or a few virus particles establish the 
productive infection [59-61]. The number of transferred particles is dependent on the 
route of transmission [49, 62]. In 80 % of the heterosexual transmissions a single virus 
established the infection while the same number in injection-drug users and MSM is 40 
% in both. CCR5 using viruses is found in most transmissions, but transmission of dual 
tropic CCR5/CXC4 using has been documented [62-64].  
 
1.3.3 Prevention 
The incidence of new infections in 2012 shows a 33 % decline compared to the 3.4 
million in 2001 [6]. The decrease is largely due to ART. However, as noted above, over 
2.3 million individuals were still infected during the year. Since no vaccine against HIV 
is available, the development of other prevention methods is continuously needed. 
 
The use of cART has been shown to prevent sexual HIV transmission in several studies 
[65]. Results from the HPTN 052 study, where cART is used in combination with 
condoms and counseling in serodiscordant couples has in the published interim results 
shown a reduction in HIV transmissions by 96.4 % [66]. Male circumcision has in 
other studies been shown to reduce acquisition efficiency [67, 68]. The use of condom 
is always an important factor to avoid sexual transmission as well as treatment of other 
sexually transmitted disease if such is present. Mother to child transmission can be 
almost completely prevented if antiretroviral treatment is given to the mother and 
prophylaxis to the infant. Avoidance of breast feeding and in some cases, Caesarean 
section can further reduce the risk of mother to child transmission [69, 70]. Even 
though each of these and other prevention methods is helpful on their own, it is clear 
that a combination of intervention strategies must be used [71, 72]. The best solution 
would be an effective and safe HIV vaccine. 
 
1.4 HIV-1 GENETIC VARIATION  
1.4.1 Coreceptors 
To infect a cell, the HIV-1 protein Env first binds to its primary receptor on the cell, the 
CD4, and then to a cellular coreceptor. The coreceptor used by HIV-1 is the C-C 
chemokine receptor type 5 (CCR5) and/or the C-X-C chemokine receptor type 4 
(CXCR4). Viruses that use CCR5 are referred to as R5 viruses and viruses using 
CXCR4 are called X4 viruses. Some viruses are dual-tropic and use both coreceptors 
and they are referred to R5X4 virus [23]. Other coreceptors have been documented in 
vitro, but only CCR5 and CXCR4 are proven to be used in vivo [62].  
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The Env protein is divided into five conserved regions (C1-C5) interspersed with five 
variable regions (V1-V5). The gp120 coding domain of the env gene evolves faster 
(changing 1–2 % per year) than any other region of the genome [73]. The variable 
regions are presented on the surface of the protein and the principal determinant of 
coreceptors use is mainly located to the variable loop 3 (V3) [74], but the V1/V2, V4 
and C4 regions have also been shown to affect the coreceptor binding [75-77]. Three 
amino acid changes, at positions 11, 24, and 25 of the 35-amino-acid-long V3 loop, are 
highly associated with the coreceptor switch [78, 79]. Positions outside the V3 loop 
have also been identified as statistically linked to changes within V3. Generally the 
genetic variation is greater after the switch, suggesting that substitutions are part of a 
more complex evolutionary pathway [80]. 
 
R5-using viruses are most often found to be the founder of a new infection, irrespective 
of the route of transmission but also X4-using and R5/X4-using virus have been 
detected in early infection. [62, 81-85]. The reason for the dominance of R5 virus is not 
fully understood. One theory is that the CCR5-using virus is preferred and selected for 
in a genetic bottleneck during transmission. A supporting fact that selection of R5-
using viruses occur during transmission is found in humans who are homozygous 
defective for CCR5 expression. This defect is mediated by a deletion of 32 base pair in 
CCR5 (CCR5Δ32) causing a premature stop codon. Despite presence of functional X4-
using virus the individuals who are homozygote for the deletion are highly protected 
from HIV-1 infection. Also individuals who are heterozygous seem to have some 
protection against the infection [86-88], but primarily show significantly slower rate of 
disease progression [89, 90]. The other theory suggests that virus type transmitted 
merely is a result of random selection. The dominance of R5-using virus is explained 
with the absence of X4-using virus in the transmitting partners. R5-viruses are most 
often the only virus present during major parts of the infection which by default results 
in the transmission of R5-using virus [91]. 
 
In 50-70 % of patients with untreated HIV infection X4 or X4R5 viruses emerge in the 
later stages of infection [92-96]. The cause of the coreceptor switch is not fully 
understood, but it is believed that the X4 viruses emerge from R5 viruses within an 
individual rather than are transmitted [97]. The coreceptor switch is associated with an 
accelerated decline of CD4 cells and a faster disease progression [97, 98]. It is not 
known if the switch to X4-using virus is a cause or/and a consequence of 
immunodeficiency [94, 99]. Longitudinal studies on a limited number of patients have 
shown the presence of minority X4-using viruses in samples obtained up to 12 months 
prior to the coreceptor switch [100].  
 
Maraviroc was the first approved CCR5-antagonist [101]. Successful treatment has 
only been shown in patients with only CC5-tropic virus. Before initiating a treatment 
regimen containing maraviroc a HIV-1 tropism test should be performed to rule out the 
presence of X4 viruses [102]. 
 
1.4.2 Tropism prediction methods  
The coreceptor use can be tested by phenotypic assays or and predicted 
bioinformatically from the sequence data (genotypic assay).  
 
In the phenotypic tests, patient derived virus is tested for its’ ability to replicate in 
specific cell lines expressing defined coreceptors. The MT-2 assay was the first widely 
used phenotypic test. In this assay peripheral blood mononuclear cells from a HIV 
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infected individual are co-cultivated together with MT-2 cells. If X4-using virus is 
present, they will infect the cells and form syncytia, while R5-using virus will not 
[103]. The disadvantages of this method are the lack of a negative control and, because 
the complete virus is used, the requirement for a biosafety level-3 facility. More recent 
phenotypic test uses parts or the entire env gene. The parts are amplified from plasma 
HIV RNA to generate recombinant virus or pseudovirions which in turn are used to 
infect human cell lines expressing CD4 and a coreceptor in cell cultures [104-106]. 
Both the virus and the cell line are usually specially engineered to allow high 
throughput, easy read-out and high reproducibility.  
 
The Trofile phenotypic assay (Monogram Biosciences) [105] is the most widely used 
method to predict HIV coreceptor tropism in the US, while most of the screening in 
patients who are candidates for maraviroc therapy in Europe is performed by in-house 
genotypic tests [107, 108]. Genotypic assays are generally faster and less expensive 
compared to phenotypic assays. 
 
Several algorithms to bioinformatically interpret the coreceptor use from the sequence 
data have been developed. The simplest method is the 11/25 charge rule. It only uses 
information of the charge of amino acids in positions 11 and 25 in the V3 loop to 
predict the virus tropism based on the finding that many X4 viruses have basic 
(positively charged) amino acids at one or both of these positions. The results show a 
moderate correlation with phenotypic tests [109]. PSSM and geno2pheno are more 
advanced prediction algorithms. Both algorithms use the amino acid sequence of entire 
V3 loop in the env-gene, and calculate scores with different methods. If the score in 
PSSM is below −6·96 the sequence is considered R5, whereas sequences with s core 
above −2·88 are predicted to be X4. In the geno2pheno the result of the interpretation is 
given as a quantitative value of the false positive rate (FPR). FPR is defined as the 
probability of classifying an R5 virus falsely as X4. Varying the FPR threshold value 
changes the sensitivity and specificity for X4 prediction. The genotypic tests have for a 
long time been based on Sanger population sequencing. One disadvantage with the 
population sequencing is the risk of minor variants present in less than 20 % of the 
population remain hidden. Such minority variants that have been shown to be of 
clinical relevance [109-112]. The majority of NGS-studies performed have used 454 
sequencing to study coreceptors tropism but PacBio, Illumina and Ion Torrent have 
been demonstrated to predict minority X4 variants at similar levels [113]. 
 
1.5 ANTIRETROVIRAL THERAPY 
1.5.1 History and current treatment 
All steps of the virus replication cycle are potential targets for ART. Since viruses are 
obligatory intracellular parasites, they are completely dependent on the availability of 
suitable host cells. The processes targeted by ART must therefore differ from the host 
cell processes so that the ART primarily affects the viral replication as interference with 
host cell functions may lead to adverse side effects. Individuals with an untreated HIV-
1 infection will in almost all cases develop AIDS which ultimately is followed by 
death, but the introduction of modern combination ART has transformed HIV infection 
into a treatable chronic disease [114]. Antiretroviral therapy suppresses the virus 
replication and thereby lowers the virus levels in the infected individual. In 1987, the 
first drug for HIV-1 infection treatment, azidothymidine (AZT), was introduced in the 
market followed by a few, similar, drugs during the early 1990’s [115-117]. In 1996, 
the morbidity and mortality in AIDS dropped [118-120] dramatically due to the 
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development of new drugs and the introduction of new combination treatment methods. 
Since then, ART is given as a combination of at least three drugs simultaneously 
attacking different steps of the replication cycle [118, 119, 121, 122]. This treatment 
strategy is often referred to as highly active antiretroviral therapy (HAART) or 
combinational antiretroviral therapy (cART). To date, around 25 antiretroviral drugs 
have been approved for use in the treatment of HIV infection by the European medicine 
agency (EMA) in Europe and/or the Food and Drug Administration (FDA) in the 
United States [123, 124]. Through cART, it is possible to suppress the plasma HIV-1 
viral load below detection limits of standard assays for quantification of plasma HIV-1 
RNA (< 20-50 RNA copies/mL). There are six distinct classes of antiretroviral drugs 
but the majority of drugs are in three of the classes, nucleoside reverse transcriptase 
inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and 
protease inhibitors (PIs) (Table 1). Both NRTIs and NNRTIs target the HIV-specific 
enzyme reverse transcriptase and inhibit its function. NRTIs are compounds similar to 
and competing with the normal substrate of RT, i.e. nucleosides, but they are altered so 
that they lack a 3´hydroxyl group which leads to chain termination of the growing viral 
DNA chain [125-127]. NNRTIs are non-competitive and block the activity of reverse 
transcriptase by binding near to the active site of reverse transcriptase [127]. Protease is 
another of HIV-1’s three essential enzymes. PIs resemble the normal peptide substrate 
of the protease and bind to the active site of enzyme and thereby inhibit the maturation 
of new viral particles, leaving them non-infective. Other drug classes are entry 
inhibitors, CCR5 antagonists, and fusion inhibitors. 
 
 In Sweden, treatment initiation is recommended when the CD4 count is < 500 cells/μl 
or if the patient experiences any of the following conditions regardless of CD4 count; 
AIDS diagnosis; some AIDS associated conditions; hepatitis B infection which 
demands treatment; non-HIV related cancer demanding cytostatic and/or radiation 
treatment; pregnancy; primary HIV-infection or a desire to minimize the transmission 
risk [19]. The first line treatment for previously untreated patients is a combination of 
two NRTIs and a PI, integrase inhibitor or NNRTI [19]. The first line treatment 
recommendations in the US are similar to the Swedish guidelines, but also include two 
NRTIs in combination with an integrase inhibitor. US treatment initiation is 
independent of the CD4 cell count and is recommended for all HIV-infected 
individuals to reduce the risk of disease progression [128]. 
 
First line treatment options in Sweden [19]: 
• abacavir/lamivudine together with atazanavir/r  
• abacavir/lamivudine together with darunavir/r  
• abacavir/lamivudine or tenofovir/emtricitabin together with efavirenz  
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Table 1. ARV approved by FDA and EMA 
Drug  Approved FDA/EMA 
NRTIs   
abacavir (ABC)  1998/1999 




lamivudine (3TC) 1995/1996 
stavudine (d4T)  1994/1996b 








delavirdine (DLV)  1997/- 
efavirenz (EFV)  1998/1999 
etravirine (ETR)  2008/2008 
nevirapine (NVP)  1996/1998 
Rilpivirine  2011/2011 
Pis 






fosamprenavir (fAMP) 2003/2004 




nelfinavir (NFV) 1997/1998c 
saquinavir (SQV)  1995/1996 
tipranavir (TPV)  2005/2005 
Fusion Inhibitor 
  enfuvirtide (T-20) 2003/2003 
Entry Inhibitor 
  maraviroc (MVC) 2007/2007 
HIV integrase strand transfer inhibitors 
raltegravir (RAL)  2007/2007 
Dolutegravir   2013/2014 
a the drug was withdrawn from the market by the manufacturer. 
b not recommended by Swedish guidelines due to side effects. 
c not recommended by Swedish guidelines due to low antiviral activity. 
 
1.5.2 Treatment failure and drug resistance 
Treatment failure is defined in three stages. 1) Virological failure occurs when plasma 
virus levels rebound or do not decrease sufficiently despite of cART. This might lead 
to 2) immunologic failure and 3) clinical failure. 
 
Viral replication can be suppressed for decades when patients are treated under 
optimal conditions. Adherence is of greatest importance and without it, the patient 
risks virological treatment failure and development of drug resistance. Other factors 
such as poor drug tolerability and drug interactions between antiretrovirals (ARVs) 
and/or other medication may also lead to virologic failure and cause the evolution of 
drug resistance [129]. 
 
The high genetic variability in an HIV-infected patient creates a pool of genetically 
distinct HIV particles. In treatment-naïve patients, minority variants (virus variants that 
constitute less than approximately 20 % of the population in plasma) may contain low 
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levels of naturally occurring drug resistance mutations. When ART is initiated such 
variants with reduced susceptibility may be selected for and thereby contribute to 
treatment failure [29, 129].  
 
Drug resistance mutations, especially those involved in development of PI resistance, 
are divided into primary and secondary mutations. Primary resistance mutations usually 
confer high level antiretroviral resistance, but are often also associated with a fitness 
cost. To compensate for the loss in fitness, secondary (compensatory) mutations may 
evolve. If successful cART is interrupted, the resistant virus usually is replaced by 
wild-type variants. The rebounding wild-type variants have been suggested to originate 
either from wild-type virus that had been archived in latently infected cells before start 
of therapy [130] or from continued evolution that leads to reversion of resistance 
mutations [131, 132].  
 
Drug resistance is unequally prone to occur for different drugs and drug classes. For 
several NNRTIs and NRTIs a single mutation is enough to cause resistance. Hence, 
these drugs have a low genetic barrier. Other drugs have a higher genetic barrier, for 
example PIs, as several mutations are needed to cause high level resistance. Resistance 
to drugs with high genetic barrier usually requires suboptimal treatment during which 
the virus gets the chance to replicate during drug-selective pressure, which leads to de 
novo evolution of resistance mutations. 
 
Drug resistant viruses can also be transmitted to newly infected individuals; this event 
is termed transmitted drug resistance (TDR). This is a clinical and epidemiological 
problem because it may contribute to failure of antiretroviral treatment. The prevalence 
varies geographically. In Sweden, 5.6 % of the newly diagnosed HIV-infections 
showed evidence of TDR [133], but most of these patients had low or moderate levels 
of resistance to one drug or drug class. In the US, the corresponding portion is 14.6 % 
[134] whilst the average in Europe is around 10 % [135]. 
 
For most of the drugs, the relevant resistance mutations and their impact on drug 
susceptibility is known. This makes it possible, and recommendable, to screen for the 
presence of drug resistant variants at diagnosis or before ART is initiated [19]. 
Resistance mutations may decrease the virus fitness. This is true for many of the drug 
classes, especially the NRTI lamivudine (3TC). For this reason, 3TC therapy is 
sometimes continued despite documented resistance to this drug. A risk if the 
replication is not completely suppressed by the other drugs used in the combination is 
that the virus might gain compensatory mutation that increase its fitness or accumulate 
more resistance mutations. 
 
1.6 NEXT GENERATION SEQUENCING 
1.6.1 History and current NGS-methods in short 
Next-generation sequencing (NGS) has revolutionized the genomics research field. 
NGS is characterized by production of very large volumes of sequence data to a 
relatively low cost at a high speed. The automated Sanger sequencing [136] is 
considered a “first generation” DNA sequencing machine and new technologies 
following, with the 454-sequencer from Roche as the first in the market, are referred to 
as “the next generation” [137].  
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NGS is used to study whole genomes but it is also possible to study smaller, selected 
genomic regions more in depth. When long fragments, such as whole genomes are 
studied the common way is to fragmentize the DNA into small parts and sequence 
them, this is referred to as the shot-gun approach. After sequencing, reads must be 
assembled, either via multiple sequence alignment or to a reference sequence.  
 
The choice of sequencing platform to some degree depends on the aim of the research 
project. There is a tradeoff between the amount of data, the read length, the accuracy of 
the generated data and the cost (Table 2). Generally, sequence platforms with high 
throughput and short reads like SOLiD and HiSeq 2000 are suitable for whole genome 
projects whilst in-depth studies of shorter regions benefit from longer reads such as the 
data from the GS-FLX Titanium (454 sequencing), Ion Torrent or pair-end sequencing 
on the MiSeq platform.  
 
Table 2. Summary of current NGS technologies.     
  454 GS-FLX 
Titanium/ 
454 GS Junior 
HiSeq 2500/ 
MiSeq 
Ion Torrent  
(PGM) 
RS II 






Emulsion PCR  
on beads 
Bridge PCR  
in situ 













Single molecule,  
real-time 
synthesis 





Average yield/run  
(Gb) 
0.45 /0.035 50-1000/ 
0.3-15 
1.2-2 0.02-0.08 
Primary error and  
































Polymerase chain reaction (PCR) is a preparatory approach used to target and amplify 
selected regions of genetic material [138]. In the PCR process, a short synthetic 
oligonucleotide is designed to bind to the target DNA in the beginning of the fragment 
of interest and another one in the end of the same fragment. The two DNA 
complementary pieces of nucleotides are called primers, because they prime the 
reaction. The genetic material in between the two primers (the amplicon) is “cut out” 
and copied many times.  
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Primer design has always been important in project where PCR amplification and/or 
DNA sequencing is used, but with the NGS technology it has become even more 
crucial. The increased possibilities to study rare variants hidden in diverse populations, 
demand primers that are placed in conserved areas of the genetic material. This is 
especially challenging in RNA viruses and other divergent viruses. Primers that do not 
capture the full population diversity and thereby favor certain variants will cause a bias 
in the result. Other factors to consider when the primers are designed for NGS are the 
longer primers (gene specific primer together with unique sample tags and platform-
specific adaptors) as well as the increased multiplexing (several samples in the same 
reaction). Both lead to a greater risk of primers and templates binding to themselves 
(forming hairpins) or to other primer/template present in the same reaction 
(dimerization).  
 
1.6.3 454 sequencing methods-UDPS 
454 sequencing was the first available NGS platform. The sequencing technology is 
based on a sequencing by synthesis chemistry called pyrosequencing [139]. The 
platform has many applications and one of them is targeted resequencing or ultra-deep 
pyrosequencing (UDPS) as it also is referred to. The methodology is described below 
and in Figure 5.  
The library preparation is the first step of the process. It is initiated by targeting the 
region of interest and attachment of the 454-specific adaptors A and B. The double 
stranded DNA is separated into two single strands and each strand is attached to a 
DNA capture bead by binding to a complementary adaptor strand. A droplet is then 
formed around the bead by shaking a mixture of oil and water. Most droplets contain 
a single DNA fragment as well as many small enzyme beads. The droplet works as a 
mini-reactor and millions of immobilized DNA copies are produced in the emulsion 
PCR (emPCR). Each bead is then washed and placed on a PicoTiterPlate for 
sequencing. One bead is loaded into one well. Bases are flown sequentially over the 
plate, always in the same order (TACG). If one or several nucleotides of the type are 
complementary to the strand, they will be incorporated and a chemi-luminescent 
signal proportional to the number of nucleotides is produced. The light signal is 
recorded by a CCD camera and converted to bar graph of light intensities called a 
flowgram. Each well generates a flowgram and translated to a sequence (also referred 
to as a read) [140]. 
 
1.6.4 Possibilities of ultra-deep sequencing 
UDPS, which also referred to as amplicon sequencing, is an application of the 454-
platform. It has frequently been used to study viruses, in particular rapidly evolving 
RNA viruses, such as HIV and hepatitis C virus (HCV). During the last years, UDPS 
has been widely used and considered to be a valuable tool to study minority variants at 
frequency below the detection limit of standard genotyping assays. However, the 
development of other sequencing techniques and platforms has continued, and currently 
the 454-platform is being phased out in virology research to be replaced with other 
platforms with even greater potential. Ion Torrent and MiSeq are two of the newer 
platforms that are replacing the 454-platform in studies of TDR, coreceptor use, 
characterize within-host evolution and drug resistance [100, 141-144].  
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Figure 5. The 454 sequencing workflow. 
 
 
1.6.5 454 sequencing limitations and overcoming errors 
Compared to Sanger sequencing the NGS methods, and especially Roche-454 
sequencing, are more error prone [145]. This is an obstacle, for example when the 
presence of drug resistance mutations in minority species in studied. It is of greatest 
importance to be able to distinguish a rare true biologic variant from a variant resulting 
from an artifact created somewhere in the cDNA synthesis, PCR or sequencing steps. 
Originally, Roche-454 error rates were estimated to 4 % for experimental samples, and 
0.6 % for test fragments but subsequent versions of Roche-454 have greatly reduced 
these error rates [146]. Several strategies to identify, characterize and overcome these 
errors have been published. These bioinformatic strategies to obtain more reliable data 
differ. One approach is to filter sequence reads with low quality prior to or during 
alignment [147-149]. Another is to use statistical approaches where single nucleotide 
variation is detected and reconstructed. [150-153]. Both in-house software and public 
programs are used, each of the methods has its’ specific pros and cons. Artificial 
recombination of templates created during the PCR also contribute to the error 
frequency and programs to bioinformatically identify these recombinants have been 
developed [150].  
 
1.6.6 Molecular tagging – Primer IDs 
Errors occur during PCR. PCR-free sequencing is rarely possible. Random sequence 
tags have been used to circumvent some of the remaining PCR artefacts [154, 155]. 
This method, where every individual molecule is tagged and resequenced was used in 
an HIV study by Jabara and colleagues [156]. The sequence tags were then referred to 
as Primer IDs. The Primer ID consisted of a stretch of randomized nucleotides (N’s) in 
the primer used for cDNA synthesis. Using this approach, the sequence reads 
originating from the same template molecule can be identified and grouped according 
to their unique Primer ID. This makes it possible to construct a consensus sequence for 
template molecules that has been resequenced three times or more. The consensus 
sequence will be free from errors even if the single reads contain random PCR 
substitution errors and PCR recombination errors. The method requires high volumes 
of data since it is based on resequencing of the template molecules. It also needs a 
sequencing technique that produces long reads because a Primer ID of a certain length 
will be added to the amplicon. The length of the Primer ID is dependent on the number 
of cDNA template in the sample. The number of unique Primer IDs must be enough to 




The specific aims of my thesis were: 
 
I. To develop a software program that designs primers from a multiple 
alignment and are suitable for next generation sequencing. 
II. To investigate the characteristics and sources of errors in data from ultra-deep 
pyrosequencing and to develop methods to reduce the error frequency. 
III. To evaluate the quality and reproducibility of the UDPS technology in 
analysis of HIV-1 pol-gene variation. 
IV. To investigate, by UDPS, the presence of drug resistance mutations in 
treatment naïve HIV-1 infected patients and the dynamic of drug resistance 
development and reversion during treatment initiation and discontinuation.  
V. To investigate if CXCR4-using virus is present as a minority species already 
during primary HIV-1 infection in patients whose virus later switches to 
CXCR4-use. 
VI. To study the utility of using an improved NGS methodology called Primer ID.  
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3 MATERIALS AND METHODS 
 
3.1 MATERIALS 
No human material was used in Paper I. 
 
In Paper II, a SG3Δenv-plasmid was diluted to a single copy, amplified and sequenced 
in three separate runs on the Genome Sequencer FLX. The amplicon contained 167 
nucleotides from the HIV-1 pol gene corresponding to the last nucleotide of amino acid 
169, amino acids 170–224, and the first nucleotide from amino acid 225 as well as the 
sample tags and the 454-specific adaptors A and B. Sequence analyses were performed 
on the total dataset of 47,693 reads obtained from UDPS. 
 
 
Figure 6. The HIV-1 genome organization and the sequence used in Papers II, III, IV 
and VI. Kindly provided by Anna Sahlberg. 
 
 
In Paper III, four plasma samples (A-D) were used. Sample A and B were used to 
study repeatability, effects of sequence direction and the influence of primer-related 
selective amplification. These samples had approximately 1,050,000 and 1,600,000 
HIV-1 RNA copies/ml, respectively. Plasma samples C and D were used to generate 
two molecular clones for studies of UDPS sensitivity and in vitro PCR recombination. 
These two clones were therefore chosen on the basis of sequence dissimilarity with the 
aim to maximize the number of informative sites. The sequence region was the same as 
in Paper II and the samples used were the same as described below in Paper IV 
(sample A, B, C and D correspond to sample 6.4, 2.5, 4.5, 3.5 in Paper IV). 
 
In Paper IV, six to eight longitudinally obtained plasma samples from six patients were 
retrospectively investigated. All patients were infected with subtype B virus and had 
experienced virological treatment failure. The patient selection was based on the 
patients’ treatment history and plasma viral load (ranging from 17,900–1,600,000 HIV-
1 RNA copies/mL). All patients had started treatment before combination ART was 
used. Their exact treatment history varied but common for all patients was the use of 
3TC, AZT and d4T. All patients, except one, were sampled before treatment was 
initiated and, all except one (not the same), underwent and were sampled during a 




In Paper V, four to nine longitudinally obtained plasma samples from each of three 
patients were retrospectively investigated. All patients were infected with subtype B 
virus and had a HIV population that switched coreceptor use from CCR5 to CXCR4. 
The information about the coreceptor use was based on the MT-2 assay, which had 
been performed when the samples were originally obtained. The MT-2 results had been 
stored in the database connected to the biobank. Patients 1 and 2 were sampled during 
PHI. Both patients were classified into Fiebig stage II based on a negative HIV 
antibody test and positive HIV antigen and HIV RNA tests. When the first sample was 
drawn from patient 3, he was classified to be in Fiebig stage IV–V based on a positive 
HIV ELISA antibody test and an incomplete Western blot profile that lacked a p31 
band. For all three patients, the remaining samples were collected both before and after 
documented coreceptor switch.  
 
In Paper VI, the SG3∆env plasmid (same as in Paper I) was used as a control to 
investigate the accuracy of the Primer ID UDPS system. Plasma samples from three 
HIV-infected patients (A, B and C) were also investigated. The patients that were 
selected for evaluation of the Primer ID method were selected from a study on 
transmitted drug resistance in Sweden. 
 
3.2 ETHICAL CONSIDERATION 
For Papers III, IV and V, an ethics application was approved (Dnr 2008/122-31/2) by 
Regional Ethical Review Board in Stockholm, Sweden and for Paper VI an ethic 
application was approved (Dnr 2007/1533) by the same board.  
 
All patients gave written or oral informed consent in accordance with the Declaration 
of Helsinki. 
 
No patient material was used for Papers I and II, therefore no ethic application or 
approval was needed.  
 
3.3 SEQUENCING 
The sequence depth of UDPS primarily depends on the number of input molecules and 
the error frequency of the sequencing method. In Paper IV, the sequencing protocol 
was carefully optimized to maximize the number of HIV RNA molecules that were 
extracted, reverse transcribed, PCR amplified and subjected to UDPS. In-house HIV 
specific primers were used together with sample-specific tags to allow multiplexing 
during sequencing. The amplicon also contained 454 specific adaptors to allow UDPS.   
 
The HIV RNA was extracted and purified. The amount of plasma used for extraction 
was adjusted according to the viral load of each sample. The number of viral templates 
(HIV-1 cDNA copy number) for each sample was quantified by limiting dilution PCR 
before UDPS so that the number of templates subjected to sequencing could be related 
to the number of UDPS sequences obtained. The protocol is presented in detail in 
Paper IV as well as in Figure 7 and was used in Papers II-VI.  
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Figure 7. Schematic illustration of the experimental setup used in Papers II-VI. 
 
 
3.3.1 Calculation of error frequencies 
The Needleman-Wunsch algorithm was used to construct pairwise alignments between 
a reference sequence, a Sanger population sequence of the SG3Δenv plasmid, and 
UDPS reads. The identity score (the number of correctly aligned bases divided by the 
total number of bases) from the pairwise comparisons were added together and divided 
by the number of sequences. 
 
We present different error frequencies derived from the same raw data in Papers II and 
IV. The different numbers are due to a difference in calculation. In Paper IV, missing 
nucleotides in reads that did cover the entire 167-basepair amplicon (short reads) were 
considered as sequencing errors and contributed to the average error frequency. In 
Paper II, we ignored such missing nucleotides in short reads which resulted in a lower 
error frequency. Other researchers have, in their papers, generally omitted how such 
missing data has been handled.  
 
3.3.2 UDPS data filtering procedure  
We designed a set of Perl scripts to filter UDPS data from reads that were likely to 
contain sequencing errors. Most other methods are based on correction of errors. Both 
approaches have their specific pros and cons. Filtering may lead to loss of data (reads), 
whereas correction algorithms may create artificial viral variants which were not 
present in the original sample.  
 
Our data filtering strategy detected variation relative to the Sanger sequence of the 
SG3Δenv plasmid in the control experiments and a population Sanger sequence for 
each of the patient samples. Each filtering step divided the sequence reads into two 
files; one file with reads that passed the filtering step and another file with reads that 
were removed by the filtering because they had characteristics associated sequencing 
errors. Some or all filtering steps were use for Paper II, III, IV and V. In Paper IV, 
statistically derived cut-offs were applied to the cleaned data. 
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1) Identification of unique UDPS reads. To simplify the data handling and reduce the 
computational time, all sequences were collapsed to unique variants. The abundance 
(i.e. number of reads) of each unique variant was added to the sequence header of that 
variant; 2) Removal of low similarity reads. The first filtering step removed reads 
with low similarity to a reference sequence, i.e. non-HIV sequences or HIV sequences 
with very low quality. We used the Needleman-Wunsch algorithm to construct pairwise 
alignments between a Sanger reference sequence, and the unique UDPS reads to obtain 
the similarity score. If the alignment identity score was below a user-defined threshold, 
the read was removed. In Papers II, III and IV, an 80 % similarity threshold was used. 
In Paper V, the corresponding threshold was 70 %, because the V3 region is more 
heterogeneous than the pol region; 3) Removal of reads with ambiguous base calls 
“N’s”. The 454-software uses the character “N” to describe an ambiguous base call. 
Huse et al. showed that reads from the Genome Sequencer 20 (454 Life Sciences, 
Branford, CT) instrument containing N’s have a higher error frequency than reads 
without ambiguous base calls [157]. Our data, that was generated using the GS-FLX 
instrument, also showed this and we therefore removed reads containing N. This was 
performed in Papers II-V; 4) Removal of reads not covering the region of interest. 
Reads that did not cover the entire region of interest (amino acids 180–220 in RT, 
position 3087 to 3206 in HxB2, GenBank accession number K03455) were removed in 
Papers III and IV. Remaining reads were imported into the GS amplicon software 
(Roche, Penzberg, Germany) and aligned; 5) Removal of reads with out-of-frame 
indels. UDPS errors frequently involve indels, especially in homopolymeric regions 
[146]. Therefore, we identified reads with out-of-frame indels and longer 
(≥6 nucleotides) frame-shifted regions. This step retained reads with indels involving 
entire codons as well as reads with short frame-shifted regions (<6 nucleotides), which 
may represent functional HIV-1 variants. The latter reads were flagged to allow visual 
inspection, which was done in Paper II. In Paper IV, a slightly modified indel filtering 
was used. Reads with in-frame indels, ±3,6,9... nucleotides were retained while reads 
with out-of-frame indels were removed; 6) Removal of reads with stop codons. 
UDPS data from coding regions that contain stop codons are likely to represent 
sequencing errors, or are otherwise evolutionary dead-ends. We would not apply this 
filter if we would have been interested in studying stop codons in UDPS data from 
clinical patient samples or if we would have studied non-coding regions; 7) Forward 
and reverse read comparisons. The tally of each unique variant in forward and 
reverse reads was compared for all variants found in Paper IV. The abundance of a 
variant was set to the sum of the forward and reverse tallies unless the frequencies of 
the forward and reverse reads differed by more than a factor 10. If it did, we made the 
assumption that a systematic error had occurred during 454 sequencing and adjusted 
the frequency to the lower of the two estimates. If a variant was found to be absent in 
either forward or reverse direction it was discarded from further analyses; 8) Manual 
inspection. The remaining alignments were manually inspected for any remaining 
sequencing errors in Papers II-V; 9) Cut-off values. In Papers III and IV, variants 
were classified as high-confidence variants if their abundance exceeded a sample-
specific cut-off value. The cut-off value was calculated using the overall average error 
frequency and the 95 % confidence interval from the SG3Δenv plasmid sequenced in 
three separate runs. In Paper IV, cut-off values were also derived for individual drug-
resistance positions. For each individual nucleotide position the average error 
frequency at that site and its’ 95 % confidence interval was obtained from the SG3Δenv 
plasmid sequenced in three separate runs. A Chi-square test with correction for 
continuity was used to evaluate if the frequencies of variants/drug resistance mutations 
were significantly higher than the observed experimental error. The variants/drug 
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3.4 MOLECULE TAGGING (PRIMER IDS) 
The depth and accuracy of the sequencing analysis is strongly influenced by the 
frequency of introduction of experimental errors before and during sequencing. We 
have developed an NGS methodology that has the potential to generate NGS data with 
greatly reduced error frequency compared to standard NGS. The methodology was 
applied to UDPS on the 454 GS-FLX platform, but could also be used on other NGS 
platforms. The generation of sequence data and the bioinformatic pipeline to process 
the data is described below. 
 
3.4.1 Experimental approach 
RNA extraction, cDNA synthesis and semi-nested PCR amplification were performed 
according to the experimental protocol presented in Paper IV and Figure 7. The key 
feature of the method is the Primer ID, a unique sequence tag that labels each template 
molecule prior to PCR amplification, Figure 8. Our Primer ID consisted of 10 
randomized nucleotides, which enables 1,048,576 unique combinations. The Primer ID 
was added to the HIV-specific reverse cDNA primer together with the 454 specific B 
adaptor. This primer was synthesized with uracils instead of thymidines, which allowed 
it to be degraded by uracil-DNA glycosylase and NaOH following cDNA synthesis. 
Sample tags were added to one of the forward PCR primers to allow multiplexing, just 
as in standard UDPS. 
 
 
Figure 8. Schematic picture of the Primer ID process. 
 
 
3.4.2 Bioinformatic approach 
The sequences were first sorted by their sample tag. Sequences containing the same 
Primer ID originated from the same template molecule and were therefore sorted into 
groups. The sequences were multiply aligned using Muscle [158] and the alignments 
for each Primer ID were used to construct strict majority-rule consensus sequences if 
the group consisted of at least three sequences. These sequences were referred to as 
consensus template sequences because they should be an accurate reflection of the 
corresponding template sequence (HIV RNA molecule) in the patient sample, with the 




Perl is a family of programming languages that have different built-in modules to make 
various tasks easier. BioPerl is a collection of Perl modules that facilitate the 
development of Perl scripts for bioinformatic applications, such as translation of 
nucleotides to amino acids and creating alignments. Perl 5 was used to handle data in 
all Papers and to clean data in Papers II-V. The programming language C was used 
for the computationally intensive dimerization risk estimation in PrimerDesign. Moose 
object-oriented programming in Perl has been used together with the Catalyst Model-
View-Controller framework to construct the web interface for PrimerDesign in Paper 
I. In-house Perl scripts were first used, but later translated to Python scripts, to analyze 
the 454 sequence data in Paper VI. 
 
3.6 PHYLOGENETIC ANALYSES 
The evolutionary relationship of the sequence variants in Paper V was analyzed using 
maximum likelihood trees. jModelTest [159] was used to find the best-fit model of 
nucleotide substitution and PhyML 3.0 [160] was used to construct the trees. The 
maximum likelihood method was chosen before other phylogenetic methods because it 
is an accurate method that works well on rapidly evolving organisms like HIV [161].  
 
3.7 TROPISM PREDICTION  
In Paper V, the coreceptor tropism of the viruses was phenotypically tested using the 
MT-2 assay at the time of sampling. Genotypic coreceptor testing was performed on 
sequences from the V3-region with the prediction algorithms PSSMx4/r5 and 
geno2pheno[co-receptor]. Variants were considered to be X4-using viruses if the PSSM 
score was greater than - 2.88 and geno2pheno predicted an X4 phenotype using a FPR 
of 2.0 % or less. The PSSM score was chosen based on the European recommended 
guidelines [102]. Other cut-offs for geno2pheno[co-receptor] were also evaluated and the 
2.0 % cut-off was chosen because it gave the highest agreement with PSSM predictions 
on our data. 
 
3.8 STATISTICAL ANALYSES 
Mann-Whitney U test was used to test whether error frequencies in homopolymeric- 
and non-homopolymeric regions were statistically significant (Paper II); Fisher exact 
test was used to test if the error frequencies of transition and transversion errors differed 
significantly (Paper II); Spearman rank correlation test was used to study the 
correlations of site-specific error frequencies between runs as well as between forward 
and reverse reads in the same run and their P-values were calculated using a z-test 
(Paper II). The repeatability of variant quantification between samples in Paper III 
was statistically tested using Bland-Altman analyses and plots. 
 
  
   23 
4 RESULTS AND DISCUSSION 
 
NGS, in general and UDPS in particular, introduced new possibilities of studying the 
genetics and evolution of HIV-1. In 2008, when I initiated my PhD-studies, the 
technique was relatively new. At that time, there was a widespread excitement 
concerning the use of the method, but it was also realized that the analysis of the large 
sequence datasets was challenging. Thus, there was also a great need to develop and 
fine tune the methodology and the downstream analyses. UDPS can be used to study 
diverse virus populations, but the utility of the method can be hampered by 
experimental errors occurring in library preparation, sequencing and analysis. This 
thesis includes six studies, Papers I to VI. The topics include characterization of the 
type and source of errors arising in UDPS, optimization of pre-UDPS protocols, 
evaluation of the UDPS system and development of novel bioinformatic methods to 
design primers and to reduce UDPS errors through a filtering strategy. We have also 
analyzed and evaluated the challenges of a new method to tag individual molecules in 
order to reduce sequencing errors. The results from these studies are presented and 
discussed below, based on the common themes across the papers. 
 
4.1 PRIMER DESIGN  
Paper I presents and discusses PrimerDesign. PrimerDesign is a computer program 
tailored to meet the requirements for primers in the settings of NGS and highly variable 
genetic targets. A vast number of commercial and non-commercial primer design 
programs were available before we initiated our work [162-169]. The large number 
reveals the importance and difficulty creating suitable primers. However, none of the 
existing programs fulfilled our requirements. In contrast to the available programs, 
PrimerDesign optimizes the construction of primer pairs with constraints including 
degenerate sites to maximize population coverage, matching of melting temperatures, 
optimizing de novo sequence length, finding optimal bio-barcodes to allow efficient 
downstream analysis, and minimizing risk of dimerization. PrimerDesign´s workflow 
follows a series of inter-connected steps. Each step is described in order as they appear:  
 
1) Determination of the primers target locations. The user inputs a multiple 
alignment and states the region of interest (ROI) together with some other optional 
parameters. The primers generated are located outside the ROI but within a distance 
constrained by the sequencing length of the intended platform. The genetic complexity 
(i.e. the number of degenerated sites for each position) is calculated and the entropy for 
the region is estimated using Shannon entropy. All potential primers are thereafter 
listed in order of result from the entropy estimations; 2) Optimization of primer 
melting temperatures (Tm). Tm is estimated using the empirical nearest-neighbor 
model with respect to the possibility of degenerated sites [170, 171]. Should the 
difference in Tm between a forward and a reverse primer be within the maximum 
allowable limit, the primer-pair is included in the list of potential constructs; 3) Adding 
bio-barcodes and adaptors. If desired, the program can be set to generate barcodes 
(also referred to as tags). These can be optimized by either a number of unique tags, a 
certain length of the tags or the edit distance (Levenshtein distance), i.e. the possible 
minimum number of nucleotide changes required to transform one tag to another is 
dependent on tag length. Adaptors can also be added by the user, either by choosing 
from existing platform specific adaptors or by manually creating new. The tags must 
not have repeated nucleotides at adjacent sites as this is known to cause misreads in 
UDPS. If adaptors are added, this is automatically controlled and constrained; 4) 
Estimation of dimerization risk. When a primer binds to other primers or to 
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themselves, primer-dimers or hairpins may be created which may cause serious 
problems in the PCR. PrimerDesign analyzes the potential dimerization risk between 
all primer constructs (primer-tag-adaptor oligomers) that will be included in the same 
reaction. The dimerization risk is evaluated as a user-defined sliding window move 
along all potential primer-primer interactions and as a user-specified fraction of bonds 
in an interaction. Thus, each step includes user settings, which may be default values, 
as well as automatic parameters used within the algorithm. The final primers are 
presented in pairs. 
 
One limitation of PrimerDesign is the restriction on tag generation. Currently, it allows 
generation of up to 200,000 tags and a tag length of 18 nucleotides. For long tags, the 
edit distance can be set up to 10. The tagging possibility is sufficient for most studies 
undertaken today, despite the restriction. An additional limitation is the risk that the 
algorithm becomes very computationally intensive, particularly if a large number of 
tags and/or a high complexity are included in the design. 
 
PrimerDesign´s strength is its ability to use multiple alignments in combination with its 
comprehensive approach. The multiple alignments make it possible to avoid 
unnecessary target bias. This is done by finding primers located in as conserved regions 
as possible. The increasing usage of multiplexed NGS is supported by PrimerDesign’s 
automatic and flexible tag and adaptor generation. The possibility to reduce the 
dimerization risks for the entire amplicon is to our knowledge a unique feature of 
PrimerDesign when compared to other similar programs. 
 
Anterior primer design programs have focused on specific needs of certain 
experimental protocols and not NGS. In these programs, only a single sequence is 
generally used to design primers (e.g., Primer3 [169]) and, as discussed previously in 
this section, the risk of undetected genetic variability could result in amplification 
biases in genetically diverse target populations. There are programs that use multiple 
alignments (e.g., GeneFisher [165]) but lack the ability to simultaneously evaluate 
primers appropriately, for instance, by matching Tm’s and dimerization risk. 
 
The development of PrimerDesign was based on our experience with 454 ultra-deep 
sequencing of HIV-1, but the program is platform independent. Thus, the software can 
be used for primer and probe design for other NGS technologies which are preceded by 
a PCR step, e.g. IonTorrent, MiSeq/HiSeq and SOLiD as well as general PCR, real-
time PCR and traditional Sanger sequencing protocols. Further, PrimerDesign can be 
used to design primers for all stages of variability in DNA-sequencing and not only for 
HIV sequencing.  
 
The results reported in Paper III emphasize the importance of primer design. In that 
study, we evaluated two carefully designed sets of primers. They targeted the same pol-
region and their ability to quantify viral variant abundance was investigated. Both sets 
of primers detected variants down to 0.2 % of the virus population. In one of the primer 
sets, which were also used for the patient samples in Paper IV, we estimated one 
variant to constitute 46 % of the population. In contrast, the same variant was only 
detected in 5.6 % of the reads with the alternative primers. We view this result as an 
indication of primer-related selective PCR amplification that occurred as a result of 
primer mismatch.  
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4.2 EVALUATION OF ULTRA-DEEP PYROSEQUENCING  
We have used UDPS to detect minority variants containing drug resistance mutations 
(Paper IV), coreceptor usage (Paper V) and acute infection (Paper V). Others have 
shown that minority HIV resistance mutations, below the detection limit of population 
Sanger sequencing, may be of clinical relevance [172-176].  
 
The resolution of our protocol and those reported in others studies is primarily 
determined by the number of input DNA templates, the error frequency of the method 
and the efficiency of data cleaning. Therefore we have focused on optimizing the 
experimental protocols in Paper IV, characterizing the type, frequency and source of 
errors and minimizing their impact in Papers II and VI. 
 
4.2.1 Pre-UDPS experimental setup 
RNA extraction, cDNA synthesis and PCR were all optimized for high recovery of 
templates in our pre-UDPS protocols. Quantification of the number of cDNA template 
was performed by a limiting dilution PCR using the very same PCR as that used for 
UDPS preparation. This template quantification showed that the number of cDNA 
molecules subjected to UDPS ranged from 2,300 to 570,000 in Paper IV and from 56 
to 93,632 in Paper V. The UDPS generated from 3,827 to 41,490 reads per sample in 
Paper IV and 279 to 32,094 reads per sample in Paper V. We experienced low 
recovery in a few of the samples which could be due to long and suboptimal storage 
conditions. Most of the samples had been stored at -70℃ or -20℃ and some samples 
had been repeatedly freeze-thawn. Consequently, for some samples the UDPS reads 
exceeded the number of cDNA templates. In many preceding and simultaneous studies, 
a low number of viral templates were used as UDPS input and often not accurately 
quantified. This in combination with low number of reads resulted in higher detection 
limits for minority viral variants in these studies. Studies carried out today are generally 
more carefully designed. In these more recent studies, the number of input molecules is 
both quantified and high enough to benefit from the advantages of UDPS. However, 
some NGS studies would still have benefitted from the use of other methodologies such 
as single genome sequencing (SGS). 
 
Overall, we sequenced a sufficient number of viral templates from the samples with 
sufficient depth to take advantage of the ability of UDPS to study minority HIV 
variants. However, in our studies we have definitely resampled the samples virus 
variants. Thus, it is important to remember that every sequence read does not 
correspond to one viral RNA template. Due to oversampling, the lower limit of 
detection of our UDPS studies were primarily limited by errors introduced during PCR 
and UDPS. 
 
4.2.2 Characteristics and source of errors in raw UDPS data   
In Paper II, an HIV-1 clone was diluted to a single copy, PCR amplified and ultra-
deep sequenced in three separate runs. The sequenced region corresponds to a part of 
the pol-gene where many drug resistance mutations are found. The same region was 
used to evaluate the performance of UDPS in Paper III and studied in the patient 
samples in Paper IV. This region was also used to examine the challenges with Primer 
ID in Paper VI.  
 
The sequence analysis presented in Paper II was performed on a complete dataset of 
47,693 UDPS reads as well as separately for forward and reverse reads from each of the 
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three UDPS runs (the reads per sample range between 2,570 and 12,092). The average 
error frequency in our raw data was 0.30 %. UDPS-induced deletions in 
homopolymeric regions were the dominating error type. A substantial part of the 
deletions were only found in the reverse sequencing direction of the same run. This 
indicates that they were introduced during the UDPS. As anticipated, we found that 
homopolymeric regions had a higher average error frequency (0.59 % per nucleotide) 
compared to non-homopolymeric regions (0.12 % per nucleotide). This result is 
consistent with the findings of others published both before and after our study [146, 
148, 157, 177, 178]. Despite this apparent difference in average error frequency, there 
was no statistically significant difference between homopolymeric and non-
homopolymeric regions. This implies that a few single positions of the homopolymeric 
regions contributed to a substantial part of the elevated error frequency. This was 
confirmed when site-specific frequencies of deletion errors in homopolymeric regions 
ranged from 0.0021 % to 20.4 %. In fact, the site-specific error frequencies, particularly 
substitutions, were unevenly distributed across the region that was sequenced. Among 
the substitution errors, transitions were more common than transversions.  
 
4.2.3 Filtering strategy  
Based on our analysis of raw data in Paper II and Paper IV, as well as previous 
publications, we developed a set of scripts that filtered reads that were likely to contain 
sequencing errors. The backbone of the filtering strategy was to remove reads 
containing: 1) less than 80 % similarity to a user-defined reference sequence, 2) 
ambiguous nucleotide calls, 3) indels, and 4) stop codons. The steps are explained in 
detail above (Materials and Methods section). The filtering step where indels were 
removed had the most pronounced effect and reduced the average error frequency 
almost 5-fold from 0.28 % to 0.058 % per nucleotide. The cleaning procedure removed 
31 % of the reads in the data for Paper II. Similar cleaning procedures for the data 
used in Papers III and V removed 20 % and 15 % respectively. In Paper IV, the data 
cleaning strategy was used together with cut-off values for high confidence variants 
which removed 30 % of the reads. 
 
Other studies have used similar approaches and removed sequences associated with 
errors while other have reconstructed haplotypes e.g. ShoRAH. The best approach 
depends on the goal of the study. A limitation of the filtering strategy is the risk of 
removing true biological variants and that some remaining substitution errors may be 
interpreted as true variants. In addition, increasing read lengths may pose a problem 
with the filtering strategy since the probability for occurrence of a sequencing error 
increases which may lead to filtering of a large proportion of the reads. This risk is also 
dependent on the type of sequence (e.g. homopolymeric /non-homopolymeric regions). 
On the other hand, error correction leads to a risk of creating new variants or changing 
true low frequency variants.  
 
4.2.4 Characteristics and source of errors in cleaned data 
The filtering strategy, as presented above in the Material and Method section, was 
applied on the SG3Δenv-plasmid. The average error frequency per nucleotide for the 
six data sets in Paper II was reduced to 0.056 %. The error frequencies estimated for 
the cleaned data from the V3-region in Paper V was about the same for both the 454 
GS FLX and the 454 GS FLX Junior Titanium platforms. 
 
In Paper II, all except two reads with indel errors were removed. Interesting to note is 
that the cleaned average error frequency is about the same as the error frequency for 
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substitutions found in the raw data (0.057 %). The difference in error frequencies 
between homopolymeric and non-homopolymeric regions was almost completely 
removed in the cleaned data. 
 
The average error frequency of transitions was 0.052 % per nucleotide and the 
corresponding number for transversions was 0.001 %, which is a 48-fold and 
significant difference. Site-specific error frequencies continued to vary across sites. 
Moderate, but significant, correlations in site-specific error frequencies were found 
when forward or reverse reads from three separate runs were compared (Spearman R= 
0.31–0.65; p=0.001). Significant correlations were found between forward and reverse 
reads within runs (Spearman R= 0.33–0.60; p=0.001). 
 
Altogether, this indicates that the PCR that preceded UDPS contributed to a substantial 
proportion of errors that remained in our cleaned UDPS data.  
 
In Paper III, we showed that the in vitro recombination rate during PCR was low. Two 
clones that differed in 13 positions were mixed in 50:50 ratio before PCR amplification. 
The mixes were used in two experiments with 10,000 and 100,000 HIV DNA templates 
as input, respectively, and the estimated recombination rates were 0.29 % and 0.89 %. 
The majority of recombinant reads were single recombinants. The recombinant variants 
were found in low frequencies and below our limit of detection in Paper IV. The 
recombination rate in our control study (Paper III) was higher than the recombination 
rate (0.09 % - 0.11 %) estimated by Tsibris et al. [149] and lower than 1.9 % presented 
by Zagordi et al. [179]. The difference in in vitro recombination estimates may be a 
result of different mixture of clones, differences in amplicon length and differences in 
PCR amplification conditions. In our and collaborators´ recent, unpublished 
experiments, we observed that the PCR recombination rate could be greatly reduced if 
the number of PCR cycles was reduced from 60 to 30, i.e. by omitting the second, 
nested PCR.     
 
Our PCR recombination studies were performed on DNA templates. This provides a 
limitation to our study as the first step in the PCR process, the cDNA synthesis where 
RNA it reverse transcribed into cDNA, is not included in our experiments. RTs are, as 
discussed in the introduction, error-prone enzymes and as a consequence our result may 
be an underestimation of true recombination. Fang and colleagues reported a 2.5 fold 
higher in vitro recombination in RT-PCR compared to DNA-PCR [180] while Metzner 
et al. did not find the RT step to particularly affect the recombination rate in a recent 
publication [177]. Our results should in our view be interpreted as showing that our 
UDPS method may be used to study genetic variants and mutational linkage at least 
over relatively short distances.  
 
4.2.5 Using the information of error frequencies 
The results from the optimized experimental protocols in Paper IV gave us the 
possibility to detect minority variants and low frequency mutations. In Paper IV, the 
number of templates that we obtained from a sample ranged from 2,300 to 570,000, this 
corresponds to a theoretical sequencing depth of 0.04 % (1/2,300). The corresponding 
numbers in Paper V ranged from 56 to 93,632 which is equivalent to a lowest 
theoretical sequencing depth of 1.8 % (1/56). However, the sequencing depth was much 
deeper for most samples. Thus, the sequencing depth for most samples was primarily 
dependent on the error frequency and not by the number of templates. 
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We carefully evaluated how to derive accurate statistical cut-off values in Paper IV. 
The use of cut-off values was supposed to allow us to better distinguish between rare, 
but genuine, sequence variants and single-site drug resistance mutations from 
sequencing artifacts. It was well known that homopolymeric regions posed a particular 
problem in pyrosequencing. When we started the study we believed that different cut-
offs should be used for homopolymeric respective non-homopolymeric regions. 
However, since this error bias was removed by our in-house cleaning strategy we did 
not need to distinguish between homopolymeric and non-homopolymeric regions. 
Instead, we used the information about the variation in site-specific error rates and 
derived individual cut-offs for all drug resistance position of interest. The average cut-
off value for drug resistance position was 0.05 %, ranging between 0.014 % and 
0.29 %. Using the same method, the cut-offs for high confidence variants was 
estimated to 0.11 % (range 0.09 to 0.21 %). With the knowledge obtained in Paper II, 
we would today instead estimate the cut-offs in Paper IV (which chronologically was 
the first published paper) based on the differences in error frequency of transition vs. 
transversion instead of individual positions. 
 
4.3 METHODS TO FURTHER REDUCE THE IMPACT OF ERRORS. 
Paper VI was a continuation of our efforts to generate reliable sequence data to study 
minority variants and low frequency mutations in different settings, e.g. in TDR. Also 
after we have been able to reduce the average error frequency with data cleaning 
(Paper II, Paper IV), substitution errors created during PCR remained.  
 
One possible method to further reduce the error frequency is to lower the number of 
PCR cycles. It is well known that the error frequency increases with an increased 
number of PCR cycles [181, 182]. Zagordi et al. and Shao et al. both reported a 
significant reduction in UDPS error frequencies in clones that were not PCR amplified 
[179, 183]. The same was shown by Di Giallonardo et al. in a recently published study. 
However, the effect that a reduced number of PCR cycles have on NGS error 
frequencies is not yet thoroughly evaluated. Besides, a certain number of PCR-cycles 
are needed to get the sufficient amount of material needed for the subsequent UDPS, 
but at the same time newer platforms and protocols such as the Nextera XL - Illumina 
pipeline allows NGS on tiny amounts (picograms) of DNA which means that PCR 
amplification cycles will be fewer.   
 
Theoretically, the use of a polymerase with higher fidelity could produce sequences 
with lower error frequencies. However, many of the existing enzymes with very high 
fidelity seem to have a lower processivity, which leads to lower sensitivity in the PCR 
step. In addition, it has been reported that polymerase with high fidelity are more prone 
to introduce in vitro recombination [183].   
 
Random barcodes, referred to as Primer IDs, can be used to circumvent some of the 
remaining PCR and sequencing errors. With this approach, every individual cDNA 
molecule is marked with a Primer ID before the PCR and UDPS step and then 
resequenced multiple times [154, 155]. This relatively new method was first presented 
in an HIV study by Jabara et al. [156]. Independently, we had started on a similar 
approach as Jabara and colleagues. Our method is described in detail in Materials and 
Methods. The method has potential to provide consensus sequences with highly 
reduced error rates compared to standard UDPS for every cDNA template sequenced. 
Another advantage of the Primer ID method is that the exact number of templates 
sequenced is directly determined. This removes both the need to quantify the number of 
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templates and the risk of overestimation of variants by repeated sampling of the same 
original variants. In Paper VI, we present some important challenges that we have 
identified when applying the Primer ID UDPS method to sequencing of a clone and 
three patient samples. The challenges we found may influence the outcome of Primer 
ID sequencing. 
 
Our first observation was that we found a very low number of consensus sequences 
despite a high number of cDNA input molecules. In the clone control experiment, less 
than two percent of input templates were sequenced and the results were similar for the 
patient samples. Skewed resampling of Primer IDs was one reason for the low number 
of recovered templates was. Some templates were sequenced several thousand times 
and others only a few times. We found several templates sequenced less than three 
times which could therefore not be used to construct consensus sequences.   
 
The second observation was that the number of sequence templates where 
overestimated due to PCR errors in Primer IDs. Theoretically, over a million unique 
Primer IDs were available (410 combinations). Despite this, we identified several 
groups of Primer IDs that differed by only one or a few nucleotides. It is statistically 
highly unlikely that such groups of closely related Primers IDs would represent 
correctly labeled template molecules. Therefore, we believe that these closely related 
Primer IDs originated from the same original template molecule and were created when 
PCR errors were introduced in the Primer IDs during PCR and/or 454 sequencing. This 
primarily occurred in templates that had been resampled many times. 
 
Finally, despite the use of Primer IDs, 21 of 35 (60 %) consensus template sequences 
from the clone were incorrect. The majority of the remaining errors were deletions in 
homopolymeric regions, mainly in a single position. The same problem was observed 
in Paper II. We believe that these errors had been introduced during UDPS because the 
mutations were present in the majority, but not all, reads from the template and because 
the errors were “typical” 454 homopolymeric errors. 
 
We, and others, have shown good repeatability for standard UDPS (Paper III). This 
indicates that the Primer ID itself or the long cDNA primers are the source of the 
skewed result. Since the Primer IDs are random, known potential problems (e.g. 
homopolymeric stretches, dimerization) cannot be avoided, which may lead to 
differences in PCR efficiency between templates labeled with different PIDs. Even 
very small differences in PCR efficiency in every cycle may be a problem because the 
differences will be magnified during PCR cycling. Designed, instead of random, Primer 
IDs, is a possible way to proceed and something we are currently testing. This approach 
was used by Shiroguchi et al. in a related experimental setup [184]. PrimerDesign, 
presented in Paper I, could be used to design Primer IDs to avoid structural problems.  
 
An additional potential source of problems is that the Primer ID tags are attached 
during, instead of before, cDNA synthesis. This leaves a window where errors may 
occur during cDNA synthesis and remain undetected. This may result in an 
overestimation of the viral quasispecies. In a recent study by Metzner and colleagues 
showed that the in vitro RT induced errors as well as recombination is a risk in the 
cDNA synthesis [177].   
 
In conclusion, Primer ID has potential to generate accurate sequence data but it is 
important to acknowledge the challenges of the methodology which needs to be 
overcome for the technique to be a truly successful solution.  
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4.4 DETECTION AND IMPACT OF MINORITY VARIANTS IN HIV-1 
The quasispecies of related, but distinct, HIV-1 variants existing in an individual 
include several minority variants. Some of these minority variants may be of clinical 
relevance. It has been shown that minority variants with resistance mutations can 
contribute to treatment failure in patients. Particularly, pre-existing minority variants 
with NNRTI resistance mutations have been shown to be of clinical significance [175, 
185-187].   
 
In Paper III, we show that minority variants can be detected by our UDPS system 
which is presented in Paper IV. In Paper III, we identified minority variants 
representing down to 0.05 % of a population in analysis from two clones mixed at 
ratios of 99.5:0.5 and 99.95:0.05. The proportions of identified minority variants were 
somewhat higher than expected in both experiments, i.e. 2.2 % and 0.31 % 
respectively. This might be due to stochastic effects or that minority strains were 
systematically overestimated. However, it cannot be excluded that the artificial 
mixtures contained slightly higher proportions of the minor virus variant than intended. 
The statistical cut-offs derived in Paper IV allowed us to consider minority viral 
variants constituting on average 0.11 % of the population as high confidence variants 
and single drug resistance mutation 0.05 % on average. 
 
The repeatability for our system was evaluated in Paper III and in conclusion we 
found that repeatability was good. All viral variants representing 0.27 % or more of the 
population were found in repeated UDPS analyses of two patient plasma samples. A 
similar degree of consistency was observed between forward and reverse reads. 
Somewhat surprisingly, the detection of major and minor variants showed similar 
repeatability.   
 
We have studied the importance of minority variants in two longitudinal patient studies. 
In Paper IV, we investigated quasispecies dynamics during suboptimal treatment, 
treatment failure and treatment interruption. In Paper V, the viral variants were studied 
from PHI until after coreceptor switch from CCR5-using to CXCR4-using viruses with 
the intention to establish whether CXCR4-using variants existed as a minority 
population during PHI and/or early infection. We also analyzed the number of variants 
that established the infection in each of the three patients.  
 
4.4.1 Pre existing drug-resistance 
Low but significant levels of the M184I, T215A and T215I (range 0.02 %-0.12 %) drug 
resistance mutations were found in the treatment-naïve patients studied in Paper IV. 
This was rather expected since these resistance mutations only require a single mutation 
from “wild-type”. With the high genetic diversity of HIV-1, these mutations are 
expected to arise spontaneously every day. We looked for, but did not identify, 
significant pre-existence of the major drug resistance mutations M184V, Y181C, 
Y188C. All of which also require a single mutation. The absence could be explained by 
an increased fitness cost for the virus or the higher limit of detection in the position of 
interest (e.g. 0.15 % for M184V compared to 0.07 % for M184I). As discussed above 
in connection with Paper II, transitions and transversions have vastly different error 
frequencies. This knowledge could have been used in Paper IV if we would have had 
the results at that time. However, both the M184V and M184I are transitions and 
suggesting that the difference in their detection is not explained by this. The cause may 
instead be a context dependent error that we have not observed, but may also be due to 
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biologic reasons. The M184I mutation is known to be a transient state in the 
development of M184V during (3TC) treatment failure. There exist several theories as 
to why M184I tends to develop first only to replace by M184V. Our data suggest that a 
higher frequency of pre-existing M184I, may originate from HIV-1s higher A->G 
mutation frequency. T215Y/F was also screened for but not found. This is however an 
amino acid change that requires two nucleotide substitutions and is therefore less likely 
to occur. 
 
4.4.2 Dynamics of HIV-1 quasispecies 
The sensitivity of the experimental method and data filtering allowed us to study virus 
variants present in >0.11 % of the population. The sequencing length also allowed us to 
study linkage between mutations and to track individual variants through time. Five of 
the six patients studied in Paper IV were sampled before initiation of ART. As 
expected, different wild-type virus variants coexisted in the pre-treatment samples. The 
virus population remained heterogeneous after initiation of treatment. During treatment 
failure, diversity gradually decreased concurrent with the evolution of specific, linked 
drug resistance mutations. Particularly, M184V-T215Y variants were found. This 
suggests that they were more fit during selective pressure from the treatment regimen, 
which consisted of 3TC, d4T and ddI. Wild-type variants were only detected in one 
patient during treatment failure, suggesting that they have very low fitness in the 
presence of ART and that the contribution is very low from the latent reservoirs, where 
wild-type virus should have be archived. The drug resistant variants were replaced by 
wild-type soon after removal of ART, which is a proof that such virus was indeed 
archived. This was not unexpected since drug resistant variants, especially many 
resistance mutations are known to have reduced fitness in the absence of drugs [130, 
188]. Thus, it is very likely that wild-type virus variants were present at levels below 
our detection limit during treatment failure.   
 
4.4.3 Transmitted virus and coreceptor switch during PHI  
Samples from the three patients taken during PHI were analyzed in Paper V. The 
samples were used to study the evolutionary relationships in the virus population. Two 
of the patients appeared to have one founder variant. The largest minority variant 
represented 0.19 % or less of the population in these two patients. These variants are 
likely to have evolved from the founder virus after transmission because the genetic 
diversity was stochastically distributed with any single variant carrying at most one or 
two mutations relative to the founder virus. In one of the patients, two or three viruses 
established the infection. The three major variants made out 47 %, 38 % and 10 % of 
the virus population, respectively. The second and third most common variants differed 
from the first variant by a minimum of four nucleotides, which makes it highly unlikely 
that they evolved after transmission. As expected, all three patients had a low genetic 
diversity during PHI. 
 
Our result is consistent with recent observations that only one or a few viruses establish 
the infection following transmission to a new host. Studies have suggested that the 
proportion of infections that are founded by a single variant differs according to route 
of transmission, with IDUs and MSM more often having two or more founding variants 
than heterosexually infected patients [49, 62]. Our patients were MSM, which means 
that it is expected to observe transmission of more than one variant in approximately 60 
% of cases. However, since we only studied three patients, no firm conclusions can be 
drawn from our data [49].  
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UDPS analysis did not show any indication on presence of X4-using minority variants 
in any of the three patients during PHI or prior coreceptor switch as detected by the 
MT-2 assay. However, the presence of X4 for a shorter time period before coreceptor 
switch cannot be excluded since the samples obtained prior to switch were drawn a 
minimum of 17 months before the switch. Bunnik and colleagues reported that X4 
variants usually evolved gradually during a 12-month period prior to overt coreceptor 
switch [100]. In agreement with this, our phylogenetic analysis indicated that the X4 
populations originated from R5 variants that evolved after the last R5-only sample was 
obtained. This strengthens the theory that a one or a few, primarily R5-using viruses are 
the predecessors of the X4 population. However, our result does not completely rule 
out the possibility that minority X4 variants transmitted and remained present at levels 
below the detection limit of our UDPS assay until overt coreceptor switch. The three 
individuals studied in Paper V had an atypical course of infection with a rapidly 
progressing immunodeficiency. This is consistent with the observed coreceptor switch, 
but again it should be stressed that the patients were too few draw any general 
conclusions.  
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5 CONCLUSIONS AND FUTURE PERSPECTIVE 
 
HIV-1 is a virus with a very variable genome. It has the ability to adapt to changes in 
the environment and thereby escape both immune pressure and suboptimal ART. NGS, 
and especially UDPS, has enabled deep sequencing studies with unprecedented 
resolution, but the technology is more error prone than traditional sequencing. 
   
The comprehensive work to identify, characterize and reduce errors as well as 
investigate the UDPS performance performed in Papers II, III and IV has allowed 
more accurate interpretations of the biological findings in Papers IV and V. It also 
encouraged us to develop the novel software in Paper I and the new method developed 
and evaluated in Paper VI. In Paper I, we developed a novel computer program, 
named PrimerDesign. It is tailored to designs primers from a multiple alignment and is 
suitable for all types of NGS that is preceded by amplification. The algorithm was 
successfully used in studies of HIV-1 and should be equally useful for designing 
primers targeting other organisms independent of the level of genetic variation. 
 
The NGS technology has enabled the entire HIV-genome to be deep sequenced. In an 
article by Henn et al. [142], the HIV genome was amplified in overlapping regions but 
with varied coverage. A possible future development for PrimerDesign is to extend the 
algorithm to find several, compatible, primer pairs in a longer region, e.g. the complete 
genome. This would save laboratory time as samples may be multiplexed and allow 
even deeper sequencing. In an ongoing project, PrimerDesign was used to design 
primers for effective and high-coverage Illumina sequencing of entire HIV-genomes. 
We optimized the pre-UDPS protocol in Paper IV and investigated the characteristics 
and sources of errors that occurred when UDPS was used to sequence a fragment of the 
HIV-1 pol gene in Paper II. Our in-house data cleaning software removed UDPS-
introduced indel errors in homopolymeric regions. The remaining errors were primarily 
substitution errors that were introduced in the PCR that preceded UDPS. Transitions 
were significantly more frequent than transversions, which will limit detection of minor 
variants and mutations in HIV-1 as well as other species. Importantly, this problem is 
applicable to all NGS platforms where sequencing is preceded by PCR. We further 
evaluated the quality and reproducibility of the UDPS technology in Paper III. We 
concluded that repeatability was good, both for majority and minority variants. In our 
experimental settings, in vitro recombination and sequencing directions posed a minor 
problem, but still needs to be considered especially for minor viral variants and studies 
of linkage between mutations. The design of primers is of particular importance in 
UDPS to avoid selective amplification which may skew the result of frequency 
estimations.  
 
Because the NGS technologies are evolving very rapidly, the 454 sequencing approach 
that we have used in this thesis is not the method we would have used if we had started 
the projects today. Instead, we would probably have decided to use Illumina or possibly 
Ion Torrent. Illumina has the advantage of a lower error frequency, higher throughput 
and an easier workflow, but shorter read length. However, the read length has increased 
and recent pair-end sequencing protocols on the MiSeq Illumina platform has a 
read length of approximately 600 bases, which is sufficient for many applications. Ion 
Torrent generates relatively long reads, but makes the same type of errors (indels) as 
454. Both are cost efficient and generates substantially more data compared to 454. The 
Pacific Biosciences´ platform is also an interesting platform, which offers very long 
read lengths, but unfortunately it also has a quite high error frequency.  
 34 
 
One limitation to cross field work, even within the same field, is the use of different 
nomenclature. With the increasing development speed, I think it is of particular interest 
to have a joint language to make analysis simpler. One example is when a script is used 
to parse a sequence file created by someone else. If no standardized method to name the 
sequences has been used, it results in problem to create automated tools for simple 
analysis, which leads to time consuming manual work. Another example is the method 
we refer to as Primer ID. At least three different names in two different research areas 
are used for the molecule tagging approach. As a contrast, the quality score associated 
with every sequenced nucleotide for Sanger sequencing and 454 sequencing are both 
called Phred but are not equivalent. 
 
Minority variants and drug resistance mutations were studied in Papers IV and V. We 
examined the presence of pre-existing drug resistance mutations in treatment-naïve 
HIV-1 patients and found very low levels of M184I, T215A and T215I, but no presence 
of M184V, Y181C, Y188C or T215Y/F. This indicated that the natural occurrence of 
these mutations was very low, i.e. below our detection limit. When patients experienced 
treatment failure almost 100 % of the wild-type virus was replaced with drug sensitive 
variants and when therapy was interrupted, 100 % of the drug resistance variants were 
replaced with wild-type. The quasispecies in patients followed from PHI to a 
coreceptor switch were investigated in Paper V. We did not find any X4-using virus 
present as a minority species during PHI. The results indicate that the X4 population 
most probably stepwise evolved de novo from the R5 populations in each of the three 
patients. 
 
Minority drug resistance mutation and minority variants of the virus coreceptor tropism 
have both been shown to play an important role in successful ART. Already today, 
detection and quantification of drug resistance is recommended for treatment 
initialization and the standard care for patients failing therapy and requiring new cART. 
I believe that we will see an increased use of NGS sequencing instruments in both 
routine and research laboratories, which will be very beneficial. Hospitals and research 
laboratories working with sequencing will have their own bench top sequencer within a 
couple of years and whole genome sequencing will be performed on more or less a 
daily basis. This scenario could benefit patients by providing additional possibilities 
and accuracy in personalized treatment. As a consequence, the cost for resistance 
testing and other sequencing will temporarily increase. Bioinformatic expertise will 
become even more needed to interpret and handle the data generated. The rapid 
development of NGS technology will require continuous development of new methods 
to adjust and take advantage of newer NGS platform, just as I have done in this project. 
Successful treatment with the CCR5-antagonist maraviroc is dependent of the presence 
of solely R5-using virus in the patient. I would recommend more studies of 
transmission pairs to further evaluate whether R5-using virus is selected for during 
transmission or not. I would not be surprised if the results show that the likelihood of 
R5 or X4 transmission is proportional to their abundance in the donor. This would of 
course support the use of coreceptor tropism prediction before treatment initiation, but 
also already at the time of diagnosis. The coreceptor use might affect when treatment 
should be initiated since X4-using virus is associated with a faster disease progression. 
The Primer ID methodology has the potential to provide highly accurate deep 
sequencing. We identified three major challenges (Paper VI); a skewed resampling of 
Primer IDs, low recovery of templates and erratic consensus sequences. These 
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problems can lead to an underestimation of the diversity of the quasispecies as well as 
skewed or incorrect results if they are not detected. As many of our other findings, our 
results concerning the Primer ID approach is not limited to HIV or virology. We are 
currently evaluating the Primer ID methodology on other NGS platforms with 
promising results. 
In the future, all parts of the sequencing process will be further optimized, from the pre-
sequencing experimental protocols, via sequencing platforms, to the data interpretation. 
Every time consuming step will be considered a bottleneck in an otherwise streamlined 
process. Read lengths will increase. Already today, the RS II from Pacific Bioscience 
generates reads with an average read length of 4,200 to 8,500 base pairs and the longest 
reads cover over 30,000 base pairs. 454 (Roche) recently presented a new improved 
chemistry, GS FLX + which is said to have the capability to generate reads up to 1,000 
bases. The error frequencies will be reduced. The Nextera XL - Illumina pipeline 
allows NGS to start from tiny amounts of DNA which reduces the PCR cycles needed 
and thereby reduces the introduction of the PCR errors. The lowered error frequencies 
will not only depend on sequencing free from errors but, just as we have attempted to 
reduce error frequency in Paper VI, other methods to circumvent the errors will be 
developed and improved. Pacific Bioscience´s sequencing libraries are made from 
circular DNA molecules with adapters (hairpin loops) ligated at both ends of the DNA 
insert, the raw sequence reads often contain multiple determinations of the DNA insert 
sequence, separated by the adapter sequences. This allows a user to extract the 
consensus sequence, but full potential of the longer read length is still blunted by 
artificial recombination occurring in the PCR that precedes sequencing. Sequence data 
will be generated faster and cheaper. I believe that the big challenge in the future is to 
efficiently carry out data analysis and store the enormous amount of data. It will be 
even more crucial to develop pipelines where as little manual work as possible is 
required.  
 
The possibilities of data storage are rapidly developing but the costs for archiving data 
can however be considerable. Storage must be done in an efficient way for two main 
reasons. Larger collaboration is often needed in these types of analysis and data must 
be possible to send between people and locations. It is also important for the 
transparency that others are able to access data after publication. Today, Sanger 
sequences and to some extent NGS data is stored in large public databases, but other 
solutions are required for the growing amounts of NGS data. Another problem with 
both transparency and comparison between studies is the lack of standardized methods 
to state which methods are being used in the particular experiment. Conclusions from 
experiments are being drawn after numerous steps data cleaning, normalization of data, 
the use of cut-off values etc., sometimes without being fully declared.  
 
Many of the applications that are being developed, including our methods and software, 
reach further than to HIV and virology. Genomics research in general would gain from 
more cross-field collaboration and interaction.  
 
In conclusion, we have developed and used new NGS and bioinformatic methods to 
study genetic variation and evolution in HIV-1. We showed that UDPS can be used to 
gain new insights in HIV evolution and to detect minority drug resistance mutations as 
well as minority variants. 
 




Many people have contributed and deserve to be acknowledged for the making of this 
thesis. During my years as a PhD-student I have learned more than I ever hoped for and 
met some wonderful persons. I would like to take the opportunity to mention some of 
you and to say “Thank you”, to all of you. 
  
Jan Albert, my supervisor. Janne, jag kunde inte ha önskat mig en bättre handledare. 
Tack för att jag har fått vara en del av din forskningsgrupp. Du har alltid haft tid och en 
öppen dörr, även när du har varit upptagen. Du är en fantastik lärare och chef. Jag 
beundrar din breda kunskap och är glad för ditt positiva synsätt på resultat. Jag är 
tacksam för att du hela tiden har uppmutrat mig till att utvecklas genom att prova nya 
saker och besöka nya platser. 
 
Thomas Leitner, my co-supervisor. Tack för att du välkomnade mig till din grupp på 
LANL och får att du alltid får mig att känna mig som att jag kan saker. Att diskutera 
vetenskap och andra livsviktiga frågor med dig har varit både underhållande och 
mycket lärorikt.  
 
Björn Andersson, my co-supervisor. Det var du som först välkomnade mig till KI. 
Tack för att jag fick vara en del av din grupp i början och för alla fortsatta givande 
samtal. 
 
Richard Neher, Thank you for great scientific collaboration and good times after 
work. I’m so glad I got the opportunity to meet you. I have felt very welcome in both 
Santa Barbara and Teubingen.  
  
Sven Britton, Ghana var fantastiskt, du gjorde det till en exceptionellt lärorik resa med 
din antusiasm och förmåga att engagera.  
 
Benita Zweygberg Wirgart, som både välkomnade oss till mikrobiologen och var en 
exemplarisk mikrobiologiexaminator. 
 
Collaborators and co-authors, Göran Bratt, Bette Korber, Mohan Krishnamoorthy, 
Gayathri Athreya, Will Fischer, Peter Hraber, Cheryl Gleasner and Lance Green. 
It has been a pleasure working with you all. 
 
Colleagues and friends at KI/KS/SMI/LANL 
Thank you/Tack till: Charlotte Hedskog, för alla gemensamma projekt som inte 
skulle kunna ha genomförts i närheten av lika bra utan dig, våra roliga resor, givande 
samtal och för att du har blivit min fina vän. Lina Thebo för all labhjälp och för att du 
förgyller mina dagar på kontoret. Mattias Mild, för din positiva energi och bra 
projektsamarbeten. Ewa Ericsson för att du har visat mig hur labarbete ska gå till och 
alltid är hjälpsam.  
 
Lina Odevall, för alla äventyr och inspirerande samtal. Det finns ingen som jag hellre 
delar skrivbord med än dig, min vän! Susanne von Stockenström, för många härliga 
och trevliga samtal på kontoret samt roliga upptåg i Seattle. Viktor Dahl för roliga och 
givande diskussioner. Sarah Palmer and Bates Gill for being so including, crazy and 
wonderful. Helena Skar för att du är så inspirerande. Alexander Hiddini, för dina 
   37 
svåra frågor som har tvingat mig att tänka efter. Salma Nowroozalizadeh, för fina 
samtal och för att du fortsätter att hålla ihop oss. Joakim Esbjörnsson, för att du alltid 
är så hjälpsam och positiv. Wendy Murillo, for always spreading happiness. Leda 
Parham, Carina Perez, Dace Balode, Melissa Norström, Marcus Buggert and Irina 
Maljkovic Berry, for all nice discussions. You have been the best roommates. Ellen 
Sherwood, för all hjälp när jag först kom till KI. Åsa Onshagen som pratade och 
skrattade sig igenom ett halvår av projektarbete och blev min fina vän. Marianne 
Jansson, Annika Karlsson, Kajsa Apetina and Maria Axelsson för hjälp med 
prover, material, glada tillrop och trevliga samtal. Lisbeth Löfstrand för ovärderlig 
administrativ hjälp.  
 
Tack till PhD Club, Therese Högfeldt och Cecilia Jädert. Det har varit ett nöje att 
arbeta tillsammans med så drivna och inspirerande tjejer som er och övriga 
medlemmar. 
  
Tack till alla mina fantastiska vänner utanför min akademiska värld. Vi har pratat oss 
igenom trevliga middagar och gått på långa och korta promenader som ger mig positiv 
energi. Ni har också gett mig värdefulla, praktiska förslag. Tack Sabina Hjerppe och 
Anna Dovärn för er ovärderliga vänskap och uppmuntran längs vägen. Ett särskilt tack 
till Anna Sahlberg som förutom att ha varit en underbar vän också har har hjälpt mig 
med bilder. Jag är så glad över att du, och din familj, så länge har varit en så fin del av 
mitt liv.  
 
Stora familjen Brodin, Ernst, Kinna, Jojjo. Anna och Lagercrantz, Svetlana, 
Karolina, Marcus, Alexander och Victor. Ernst, tack för en bra introduktion till KI 
som jag aldrig skulle ha fått utan dig. Tack till er alla för uppmuntran och framför allt 
för att jag har fått en så extrafamilj.  
 
Mamma, Matilda och Emelie med fina familjer. Tack för all uppmuntran och för att 
ni alltid bara är ett telefonsamtal bort. 
 
Pappa – Tack för allt stöd, för alla heja-på samtal, för att du alltid har trott på mig och 
fått mig att känna mig att att jag kan göra precis vad jag vill. 
 
Min bästaste, underbara familj. Kristofer, jag är så glad över att ha dig vid min sida. 
Jag skulle aldrig ha gjort den här resan utan din uppmuntran. Tack för all värdefull 
hjälp under vägen och med avhandlingen. Theodor, världens finaste, finaste lille kille. 
Du får mig att vilja göra allting lite bättre. Tack för all kärlek från er båda. Nu fortsätter 








1. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men--New 
York City and California. MMWR Morb Mortal Wkly Rep 1981,30:305-308. 
2. Greene WC. A history of AIDS: looking back to see ahead. Eur J Immunol 
2007,37 Suppl 1:S94-102. 
3. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et 
al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired 
immune deficiency syndrome (AIDS). Science 1983,220:868-871. 
4. Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, et 
al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from 
patients with AIDS and at risk for AIDS. Science 1984,224:500-503. 
5. Popovic M, Sarngadharan MG, Read E, Gallo RC. Detection, isolation, and 
continuous production of cytopathic retroviruses (HTLV-III) from patients with 
AIDS and pre-AIDS. Science 1984,224:497-500. 
6. UNAIDS. UNAIDS Report on the Global AIDS Epidemic- 2013. In; 2013. 
7. Sharp PM, Hahn BH. The evolution of HIV-1 and the origin of AIDS. Philos 
Trans R Soc Lond B Biol Sci 2010,365:2487-2494. 
8. Andersson S, Norrgren H, da Silva Z, Biague A, Bamba S, Kwok S, et al. 
Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in 
Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-
2 infection than in HIV-1 infection. Arch Intern Med 2000,160:3286-3293. 
9. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, et al. Reduced rate of 
disease development after HIV-2 infection as compared to HIV-1. Science 
1994,265:1587-1590. 
10. Hahn BH, Shaw GM, De Cock KM, Sharp PM. AIDS as a zoonosis: scientific 
and public health implications. Science 2000,287:607-614. 
11. Worobey M, Gemmel M, Teuwen DE, Haselkorn T, Kunstman K, Bunce M, et 
al. Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature 
2008,455:661-664. 
12. Taylor BS, Hammer SM. The challenge of HIV-1 subtype diversity. N Engl J 
Med 2008,359:1965-1966. 
13. Peeters M, Jung M, Ayouba A. The origin and molecular epidemiology of HIV. 
Expert Rev Anti Infect Ther 2013,11:885-896. 
14. De Leys R, Vanderborght B, Vanden Haesevelde M, Heyndrickx L, van Geel 
A, Wauters C, et al. Isolation and partial characterization of an unusual human 
immunodeficiency retrovirus from two persons of west-central African origin. J 
Virol 1990,64:1207-1216. 
15. Gurtler LG, Hauser PH, Eberle J, von Brunn A, Knapp S, Zekeng L, et al. A 
new subtype of human immunodeficiency virus type 1 (MVP-5180) from 
Cameroon. J Virol 1994,68:1581-1585. 
16. Simon F, Mauclere P, Roques P, Loussert-Ajaka I, Muller-Trutwin MC, 
Saragosti S, et al. Identification of a new human immunodeficiency virus type 1 
distinct from group M and group O. Nat Med 1998,4:1032-1037. 
17. Vallari A, Bodelle P, Ngansop C, Makamche F, Ndembi N, Mbanya D, et al. 
Four new HIV-1 group N isolates from Cameroon: Prevalence continues to be 
low. AIDS Res Hum Retroviruses 2010,26:109-115. 
18. Plantier JC, Leoz M, Dickerson JE, De Oliveira F, Cordonnier F, Lemee V, et 
al. A new human immunodeficiency virus derived from gorillas. Nat Med 
2009,15:871-872. 
   39 
19. RAV RfAT. Antiretroviral behandling av HIV-infektion 2013, uppdaterad 
version 2014-02-10. In; 2013. 
20. Folkhälsomyndigheten. HIV-infektion-epidemiska årsrapport 2012-2013. In; 
2013. 
21. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R. 
The T4 gene encodes the AIDS virus receptor and is expressed in the immune 
system and the brain. Cell 1986,47:333-348. 
22. McDougal JS, Kennedy MS, Sligh JM, Cort SP, Mawle A, Nicholson JK. 
Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral 
protein and the T4 molecule. Science 1986,231:382-385. 
23. Berger EA, Doms RW, Fenyo EM, Korber BT, Littman DR, Moore JP, et al. A 
new classification for HIV-1. Nature 1998,391:240. 
24. Wilen CB, Tilton JC, Doms RW. HIV: cell binding and entry. Cold Spring 
Harb Perspect Med 2012,2. 
25. Duffy S, Shackelton LA, Holmes EC. Rates of evolutionary change in viruses: 
patterns and determinants. Nat Rev Genet 2008,9:267-276. 
26. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. 
Evolutionary and immunological implications of contemporary HIV-1 
variation. Br Med Bull 2001,58:19-42. 
27. Lauring AS, Andino R. Quasispecies theory and the behavior of RNA viruses. 
PLoS Pathog 2010,6:e1001005. 
28. Eigen M, Schuster P. The hypercycle. A principle of natural self-organization. 
Part A: Emergence of the hypercycle. Naturwissenschaften 1977,64:541-565. 
29. Meyerhans A, Cheynier R, Albert J, Seth M, Kwok S, Sninsky J, et al. 
Temporal fluctuations in HIV quasispecies in vivo are not reflected by 
sequential HIV isolations. Cell 1989,58:901-910. 
30. Coffin J, Swanstrom R. HIV pathogenesis: dynamics and genetics of viral 
populations and infected cells. Cold Spring Harb Perspect Med 
2013,3:a012526. 
31. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral 
dynamics in human immunodeficiency virus type 1 infection. Nature 
1995,373:117-122. 
32. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 
dynamics in vivo: virion clearance rate, infected cell life-span, and viral 
generation time. Science 1996,271:1582-1586. 
33. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. 
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. 
Nature 1995,373:123-126. 
34. Preston BD. Reverse transcriptase fidelity and HIV-1 variation. Science 
1997,275:228-229; author reply 230-221. 
35. Mansky LM, Temin HM. Lower in vivo mutation rate of human 
immunodeficiency virus type 1 than that predicted from the fidelity of purified 
reverse transcriptase. J Virol 1995,69:5087-5094. 
36. O'Neil PK, Sun G, Yu H, Ron Y, Dougherty JP, Preston BD. Mutational 
analysis of HIV-1 long terminal repeats to explore the relative contribution of 
reverse transcriptase and RNA polymerase II to viral mutagenesis. J Biol Chem 
2002,277:38053-38061. 
37. Abram ME, Ferris AL, Shao W, Alvord WG, Hughes SH. Nature, position, and 
frequency of mutations made in a single cycle of HIV-1 replication. J Virol 
2010,84:9864-9878. 
 40 
38. Shriner D, Shankarappa R, Jensen MA, Nickle DC, Mittler JE, Margolick JB, et 
al. Influence of random genetic drift on human immunodeficiency virus type 1 
env evolution during chronic infection. Genetics 2004,166:1155-1164. 
39. Svarovskaia ES, Cheslock SR, Zhang WH, Hu WS, Pathak VK. Retroviral 
mutation rates and reverse transcriptase fidelity. Front Biosci 2003,8:d117-134. 
40. Neher RA, Leitner T. Recombination rate and selection strength in HIV intra-
patient evolution. PLoS Comput Biol 2010,6:e1000660. 
41. Kimura M. Change of gene frequencies by natural selection under population 
number regulation. Proc Natl Acad Sci U S A 1978,75:1934-1937. 
42. Tindall B, Cooper DA. Primary HIV infection: host responses and intervention 
strategies. AIDS 1991,5:1-14. 
43. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic 
features of primary HIV infection. Ann Intern Med 1996,125:257-264. 
44. Ribeiro RM, Qin L, Chavez LL, Li D, Self SG, Perelson AS. Estimation of the 
initial viral growth rate and basic reproductive number during acute HIV-1 
infection. J Virol 2010,84:6096-6102. 
45. Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, Knight HL, et 
al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral 
replication in SIV infection. Science 1998,280:427-431. 
46. Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, McNeil A, et al. 
Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human 
immunodeficiency virus type 1 infection and substantial delay in restoration 
following highly active antiretroviral therapy. J Virol 2003,77:11708-11717. 
47. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, et al. 
CD4+ T cell depletion during all stages of HIV disease occurs predominantly in 
the gastrointestinal tract. J Exp Med 2004,200:749-759. 
48. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. 
Nature 2010,464:217-223. 
49. Shaw GM, Hunter E. HIV transmission. Cold Spring Harb Perspect Med 
2012,2. 
50. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, et 
al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: 
implications for diagnosis and staging of primary HIV infection. AIDS 
2003,17:1871-1879. 
51. Lifson AR, Buchbinder SP, Sheppard HW, Mawle AC, Wilber JC, Stanley M, 
et al. Long-term human immunodeficiency virus infection in asymptomatic 
homosexual and bisexual men with normal CD4+ lymphocyte counts: 
immunologic and virologic characteristics. J Infect Dis 1991,163:959-965. 
52. Hladik F, McElrath MJ. Setting the stage: host invasion by HIV. Nat Rev 
Immunol 2008,8:447-457. 
53. Powers KA, Poole C, Pettifor AE, Cohen MS. Rethinking the heterosexual 
infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis 
2008,8:553-563. 
54. Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, et al. 
Heterosexual risk of HIV-1 infection per sexual act: systematic review and 
meta-analysis of observational studies. Lancet Infect Dis 2009,9:118-129. 
55. Muessig KE, Smith MK, Powers KA, Lo YR, Burns DN, Grulich AE, et al. 
Does ART prevent HIV transmission among MSM? AIDS 2012,26:2267-2273. 
56. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen 
F, et al. Viral load and heterosexual transmission of human immunodeficiency 
virus type 1. Rakai Project Study Group. N Engl J Med 2000,342:921-929. 
   41 
57. Fideli US, Allen SA, Musonda R, Trask S, Hahn BH, Weiss H, et al. Virologic 
and immunologic determinants of heterosexual transmission of human 
immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses 
2001,17:901-910. 
58. Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV 
transmission. Nat Rev Microbiol 2004,2:33-42. 
59. Wolfs TF, Zwart G, Bakker M, Goudsmit J. HIV-1 genomic RNA 
diversification following sexual and parenteral virus transmission. Virology 
1992,189:103-110. 
60. Wolinsky SM, Wike CM, Korber BT, Hutto C, Parks WP, Rosenblum LL, et 
al. Selective transmission of human immunodeficiency virus type-1 variants 
from mothers to infants. Science 1992,255:1134-1137. 
61. Ping LH, Joseph SB, Anderson JA, Abrahams MR, Salazar-Gonzalez JF, 
Kincer LP, et al. Comparison of viral Env proteins from acute and chronic 
infections with subtype C human immunodeficiency virus type 1 identifies 
differences in glycosylation and CCR5 utilization and suggests a new strategy 
for immunogen design. J Virol 2013,87:7218-7233. 
62. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, 
et al. Identification and characterization of transmitted and early founder virus 
envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 
2008,105:7552-7557. 
63. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, et al. 
Human immunodeficiency virus type 1 env clones from acute and early subtype 
B infections for standardized assessments of vaccine-elicited neutralizing 
antibodies. J Virol 2005,79:10108-10125. 
64. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H, et al. 
Genetic identity, biological phenotype, and evolutionary pathways of 
transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 
2009,206:1273-1289. 
65. Cohen MS, Smith MK, Muessig KE, Hallett TB, Powers KA, Kashuba AD. 
Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we 
go from here? Lancet 2013,382:1515-1524. 
66. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, 
Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral 
therapy. N Engl J Med 2011,365:493-505. 
67. Gray R, Kigozi G, Kong X, Ssempiija V, Makumbi F, Wattya S, et al. The 
effectiveness of male circumcision for HIV prevention and effects on risk 
behaviors in a posttrial follow-up study. AIDS 2012,26:609-615. 
68. Quinn TC. Circumcision and HIV transmission. Curr Opin Infect Dis 
2007,20:33-38. 
69. Medrano J, Soriano V. [Mother-to-child transmission of HIV infection in the 
era of highly active antiretroviral therapy]. Med Clin (Barc) 2009,132:505-506. 
70. Kourtis AP, Lee FK, Abrams EJ, Jamieson DJ, Bulterys M. Mother-to-child 
transmission of HIV-1: timing and implications for prevention. Lancet Infect 
Dis 2006,6:726-732. 
71. McNairy ML, Cohen M, El-Sadr WM. Antiretroviral therapy for prevention is a 
combination strategy. Curr HIV/AIDS Rep 2013,10:152-158. 
72. Coates TJ, Richter L, Caceres C. Behavioural strategies to reduce HIV 
transmission: how to make them work better. Lancet 2008,372:669-684. 
73. Leitner T, Kumar S, Albert J. Tempo and mode of nucleotide substitutions in 
gag and env gene fragments in human immunodeficiency virus type 1 
populations with a known transmission history. J Virol 1997,71:4761-4770. 
 42 
74. Bagnarelli P, Mazzola F, Menzo S, Montroni M, Butini L, Clementi M. Host-
specific modulation of the selective constraints driving human 
immunodeficiency virus type 1 env gene evolution. J Virol 1999,73:3764-3777. 
75. Carrillo A, Ratner L. Cooperative effects of the human immunodeficiency virus 
type 1 envelope variable loops V1 and V3 in mediating infectivity for T cells. J 
Virol 1996,70:1310-1316. 
76. Jansson M, Backstrom E, Scarlatti G, Bjorndal A, Matsuda S, Rossi P, et al. 
Length variation of glycoprotein 120 V2 region in relation to biological 
phenotypes and coreceptor usage of primary HIV type 1 isolates. AIDS Res 
Hum Retroviruses 2001,17:1405-1414. 
77. Labrosse B, Treboute C, Brelot A, Alizon M. Cooperation of the V1/V2 and V3 
domains of human immunodeficiency virus type 1 gp120 for interaction with 
the CXCR4 receptor. J Virol 2001,75:5457-5464. 
78. de Jong JJ, Goudsmit J, Keulen W, Klaver B, Krone W, Tersmette M, et al. 
Human immunodeficiency virus type 1 clones chimeric for the envelope V3 
domain differ in syncytium formation and replication capacity. J Virol 
1992,66:757-765. 
79. Milich L, Margolin BH, Swanstrom R. Patterns of amino acid variability in 
NSI-like and SI-like V3 sequences and a linked change in the CD4-binding 
domain of the HIV-1 Env protein. Virology 1997,239:108-118. 
80. Arrildt KT, Joseph SB, Swanstrom R. The HIV-1 env protein: a coat of many 
colors. Curr HIV/AIDS Rep 2012,9:52-63. 
81. Chalmet K, Dauwe K, Foquet L, Baatz F, Seguin-Devaux C, Van Der Gucht B, 
et al. Presence of CXCR4-using HIV-1 in patients with recently diagnosed 
infection: correlates and evidence for transmission. J Infect Dis 2012,205:174-
184. 
82. Raymond S, Delobel P, Mavigner M, Cazabat M, Encinas S, Souyris C, et al. 
CXCR4-using viruses in plasma and peripheral blood mononuclear cells during 
primary HIV-1 infection and impact on disease progression. AIDS 
2010,24:2305-2312. 
83. Fiore JR, Bjorndal A, Peipke KA, Di Stefano M, Angarano G, Pastore G, et al. 
The biological phenotype of HIV-1 is usually retained during and after sexual 
transmission. Virology 1994,204:297-303. 
84. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, et al. Genotypic and 
phenotypic characterization of HIV-1 patients with primary infection. Science 
1993,261:1179-1181. 
85. Abbate I, Vlassi C, Rozera G, Bruselles A, Bartolini B, Giombini E, et al. 
Detection of quasispecies variants predicted to use CXCR4 by ultra-deep 
pyrosequencing during early HIV infection. AIDS 2011,25:611-617. 
86. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, et al. 
Genetic restriction of HIV-1 infection and progression to AIDS by a deletion 
allele of the CKR5 structural gene. Hemophilia Growth and Development 
Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, 
San Francisco City Cohort, ALIVE Study. Science 1996,273:1856-1862. 
87. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, et al. 
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of 
the CCR-5 chemokine receptor gene. Nature 1996,382:722-725. 
88. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. 
Homozygous defect in HIV-1 coreceptor accounts for resistance of some 
multiply-exposed individuals to HIV-1 infection. Cell 1996,86:367-377. 
   43 
89. Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, et al. Long-
term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N 
Engl J Med 2009,360:692-698. 
90. Piacentini L, Biasin M, Fenizia C, Clerici M. Genetic correlates of protection 
against HIV infection: the ally within. J Intern Med 2009,265:110-124. 
91. Hedskog C, Mild M, Albert J. Transmission of the X4 phenotype of HIV-1: is 
there evidence against the "random transmission" hypothesis? J Infect Dis 
2012,205:163-165. 
92. Koot M, Vos AH, Keet RP, de Goede RE, Dercksen MW, Terpstra FG, et al. 
HIV-1 biological phenotype in long-term infected individuals evaluated with an 
MT-2 cocultivation assay. AIDS 1992,6:49-54. 
93. Karlsson A, Parsmyr K, Sandstrom E, Fenyo EM, Albert J. MT-2 cell tropism 
as prognostic marker for disease progression in human immunodeficiency virus 
type 1 infection. J Clin Microbiol 1994,32:364-370. 
94. Schuitemaker H, van 't Wout AB, Lusso P. Clinical significance of HIV-1 
coreceptor usage. J Transl Med 2011,9 Suppl 1:S5. 
95. Esbjornsson J, Mansson F, Martinez-Arias W, Vincic E, Biague AJ, da Silva 
ZJ, et al. Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during 
late-stage disease--indication of an evolving epidemic in West Africa. 
Retrovirology 2010,7:23. 
96. Bratt G, Karlsson A, Leandersson AC, Albert J, Wahren B, Sandstrom E. 
Treatment history and baseline viral load, but not viral tropism or CCR-5 
genotype, influence prolonged antiviral efficacy of highly active antiretroviral 
treatment. AIDS 1998,12:2193-2202. 
97. Verhofstede C, Nijhuis M, Vandekerckhove L. Correlation of coreceptor usage 
and disease progression. Curr Opin HIV AIDS 2012,7:432-439. 
98. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in 
coreceptor use correlates with disease progression in HIV-1--infected 
individuals. J Exp Med 1997,185:621-628. 
99. Moore JP, Kitchen SG, Pugach P, Zack JA. The CCR5 and CXCR4 
coreceptors--central to understanding the transmission and pathogenesis of 
human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 
2004,20:111-126. 
100. Bunnik EM, Swenson LC, Edo-Matas D, Huang W, Dong W, Frantzell A, et al. 
Detection of inferred CCR5- and CXCR4-using HIV-1 variants and 
evolutionary intermediates using ultra-deep pyrosequencing. PLoS Pathog 
2011,7:e1002106. 
101. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, et al. Maraviroc 
(UK-427,857), a potent, orally bioavailable, and selective small-molecule 
inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human 
immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 
2005,49:4721-4732. 
102. Vandekerckhove LP, Wensing AM, Kaiser R, Brun-Vezinet F, Clotet B, De 
Luca A, et al. European guidelines on the clinical management of HIV-1 
tropism testing. Lancet Infect Dis 2011,11:394-407. 
103. Kootstra NA, Schuitemaker H. Determination of cell tropism of HIV-1. 
Methods Mol Biol 2005,304:317-325. 
104. Trouplin V, Salvatori F, Cappello F, Obry V, Brelot A, Heveker N, et al. 
Determination of coreceptor usage of human immunodeficiency virus type 1 
from patient plasma samples by using a recombinant phenotypic assay. J Virol 
2001,75:251-259. 
 44 
105. Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, Wrin T, et al. 
Development and characterization of a novel single-cycle recombinant-virus 
assay to determine human immunodeficiency virus type 1 coreceptor tropism. 
Antimicrob Agents Chemother 2007,51:566-575. 
106. Raymond S, Delobel P, Mavigner M, Cazabat M, Souyris C, Encinas S, et al. 
Development and performance of a new recombinant virus phenotypic entry 
assay to determine HIV-1 coreceptor usage. J Clin Virol 2010,47:126-130. 
107. Obermeier M, Symons J, Wensing AM. HIV population genotypic tropism 
testing and its clinical significance. Curr Opin HIV AIDS 2012,7:470-477. 
108. Poveda E, Alcami J, Paredes R, Cordoba J, Gutierrez F, Llibre JM, et al. 
Genotypic determination of HIV tropism - clinical and methodological 
recommendations to guide the therapeutic use of CCR5 antagonists. AIDS Rev 
2010,12:135-148. 
109. Low AJ, Dong W, Chan D, Sing T, Swanstrom R, Jensen M, et al. Current V3 
genotyping algorithms are inadequate for predicting X4 co-receptor usage in 
clinical isolates. AIDS 2007,21:F17-24. 
110. Swenson LC, Moores A, Low AJ, Thielen A, Dong W, Woods C, et al. 
Improved detection of CXCR4-using HIV by V3 genotyping: application of 
population-based and "deep" sequencing to plasma RNA and proviral DNA. J 
Acquir Immune Defic Syndr 2010,54:506-510. 
111. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, et al. 
Multiple, linked human immunodeficiency virus type 1 drug resistance 
mutations in treatment-experienced patients are missed by standard genotype 
analysis. J Clin Microbiol 2005,43:406-413. 
112. Poveda E, Seclen E, Gonzalez Mdel M, Garcia F, Chueca N, Aguilera A, et al. 
Design and validation of new genotypic tools for easy and reliable estimation of 
HIV tropism before using CCR5 antagonists. J Antimicrob Chemother 
2009,63:1006-1010. 
113. Archer J, Weber J, Henry K, Winner D, Gibson R, Lee L, et al. Use of four 
next-generation sequencing platforms to determine HIV-1 coreceptor tropism. 
PLoS One 2012,7:e49602. 
114. Ray M, Logan R, Sterne JA, Hernandez-Diaz S, Robins JM, Sabin C, et al. The 
effect of combined antiretroviral therapy on the overall mortality of HIV-
infected individuals. AIDS 2010,24:123-137. 
115. Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. Cold Spring Harb 
Perspect Med 2012,2:a007161. 
116. Gershon D. Green light for ddI. Nature 1991,353:589. 
117. Young FE. The role of the FDA in the effort against AIDS. Public Health Rep 
1988,103:242-245. 
118. Palella FJ, Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, 
et al. Declining morbidity and mortality among patients with advanced human 
immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl 
J Med 1998,338:853-860. 
119. Staszewski S, Miller V, Rehmet S, Stark T, De Cree J, De Brabander M, et al. 
Virological and immunological analysis of a triple combination pilot study with 
loviride, lamivudine and zidovudine in HIV-1-infected patients. AIDS 
1996,10:F1-7. 
120. Palella FJ, Jr., Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et 
al. Mortality in the highly active antiretroviral therapy era: changing causes of 
death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 
2006,43:27-34. 
   45 
121. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, et 
al. Treatment of human immunodeficiency virus infection with saquinavir, 
zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 
1996,334:1011-1017. 
122. D'Aquila RT, Hughes MD, Johnson VA, Fischl MA, Sommadossi JP, Liou SH, 
et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and 
didanosine in patients with HIV-1 infection. A randomized, double-blind, 
placebo-controlled trial. National Institute of Allergy and Infectious Diseases 
AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med 
1996,124:1019-1030. 
123. EMA. European public assessment reports. In; 2014. 
124. FDA. Antiretroviral drugs used in the treatment of HIV infection. In; 2014. 
125. Furman PA, Barry DW. Spectrum of antiviral activity and mechanism of action 
of zidovudine. An overview. Am J Med 1988,85:176-181. 
126. Cheng YC, Dutschman GE, Bastow KF, Sarngadharan MG, Ting RY. Human 
immunodeficiency virus reverse transcriptase. General properties and its 
interactions with nucleoside triphosphate analogs. J Biol Chem 1987,262:2187-
2189. 
127. Richman DD. HIV chemotherapy. Nature 2001,410:995-1001. 
128. AIDSinfo. Adult and adolescent ARV guidelines. In. Edited by Services 
DoHaH; 2014. 
129. Coffin JM. HIV population dynamics in vivo: implications for genetic 
variation, pathogenesis, and therapy. Science 1995,267:483-489. 
130. Joos B, Fischer M, Kuster H, Pillai SK, Wong JK, Boni J, et al. HIV rebounds 
from latently infected cells, rather than from continuing low-level replication. 
Proc Natl Acad Sci U S A 2008,105:16725-16730. 
131. Kitchen CM, Lu J, Suchard MA, Hoh R, Martin JN, Kuritzkes DR, et al. 
Continued evolution in gp41 after interruption of enfuvirtide in subjects with 
advanced HIV type 1 disease. AIDS Res Hum Retroviruses 2006,22:1260-1266. 
132. Paredes R, Sagar M, Marconi VC, Hoh R, Martin JN, Parkin NT, et al. In vivo 
fitness cost of the M184V mutation in multidrug-resistant human 
immunodeficiency virus type 1 in the absence of lamivudine. J Virol 
2009,83:2038-2043. 
133. Karlsson A, Bjorkman P, Bratt G, Ekvall H, Gisslen M, Sonnerborg A, et al. 
Low prevalence of transmitted drug resistance in patients newly diagnosed with 
HIV-1 infection in Sweden 2003-2010. PLoS One 2012,7:e33484. 
134. Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, Bodnar UR, et al. 
Prevalence of transmitted drug resistance associated mutations and HIV-1 
subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS 2010,24:1203-1212. 
135. Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, Hamouda 
O, et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect 
Dis 2009,200:1503-1508. 
136. Sanger F, Coulson AR. A rapid method for determining sequences in DNA by 
primed synthesis with DNA polymerase. J Mol Biol 1975,94:441-448. 
137. Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet 
2010,11:31-46. 
138. Albert TJ, Molla MN, Muzny DM, Nazareth L, Wheeler D, Song X, et al. 
Direct selection of human genomic loci by microarray hybridization. Nat 
Methods 2007,4:903-905. 
139. Ronaghi M, Uhlen M, Nyren P. A sequencing method based on real-time 
pyrophosphate. Science 1998,281:363, 365. 
140. How-genome-sequencing-is-done-FINAL.pdf. In: 454 Life Sciences. 
 46 
141. Bull RA, Luciani F, McElroy K, Gaudieri S, Pham ST, Chopra A, et al. 
Sequential bottlenecks drive viral evolution in early acute hepatitis C virus 
infection. PLoS Pathog 2011,7:e1002243. 
142. Henn MR, Boutwell CL, Charlebois P, Lennon NJ, Power KA, Macalalad AR, 
et al. Whole genome deep sequencing of HIV-1 reveals the impact of early 
minor variants upon immune recognition during acute infection. PLoS Pathog 
2012,8:e1002529. 
143. Bar KJ, Li H, Chamberland A, Tremblay C, Routy JP, Grayson T, et al. Wide 
variation in the multiplicity of HIV-1 infection among injection drug users. J 
Virol 2010,84:6241-6247. 
144. Poon AF, Swenson LC, Bunnik EM, Edo-Matas D, Schuitemaker H, van 't 
Wout AB, et al. Reconstructing the dynamics of HIV evolution within hosts 
from serial deep sequence data. PLoS Comput Biol 2012,8:e1002753. 
145. McElroy K, Thomas T, Luciani F. Deep sequencing of evolving pathogen 
populations: applications, errors, and bioinformatic solutions. Microb Inform 
Exp 2014,4:1. 
146. Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, Bemben LA, et al. 
Genome sequencing in microfabricated high-density picolitre reactors. Nature 
2005,437:376-380. 
147. Jerome M, Noirot C, Klopp C. Assessment of replicate bias in 454 
pyrosequencing and a multi-purpose read-filtering tool. BMC Res Notes 
2011,4:149. 
148. Rozera G, Abbate I, Bruselles A, Vlassi C, D'Offizi G, Narciso P, et al. 
Massively parallel pyrosequencing highlights minority variants in the HIV-1 
env quasispecies deriving from lymphomonocyte sub-populations. 
Retrovirology 2009,6:15. 
149. Tsibris AM, Korber B, Arnaout R, Russ C, Lo CC, Leitner T, et al. Quantitative 
deep sequencing reveals dynamic HIV-1 escape and large population shifts 
during CCR5 antagonist therapy in vivo. PLoS One 2009,4:e5683. 
150. Quince C, Lanzen A, Davenport RJ, Turnbaugh PJ. Removing noise from 
pyrosequenced amplicons. BMC Bioinformatics 2011,12:38. 
151. Zagordi O, Geyrhofer L, Roth V, Beerenwinkel N. Deep sequencing of a 
genetically heterogeneous sample: local haplotype reconstruction and read error 
correction. J Comput Biol 2010,17:417-428. 
152. McElroy K, Zagordi O, Bull R, Luciani F, Beerenwinkel N. Accurate single 
nucleotide variant detection in viral populations by combining probabilistic 
clustering with a statistical test of strand bias. BMC Genomics 2013,14:501. 
153. Macalalad AR, Zody MC, Charlebois P, Lennon NJ, Newman RM, Malboeuf 
CM, et al. Highly sensitive and specific detection of rare variants in mixed viral 
populations from massively parallel sequence data. PLoS Comput Biol 
2012,8:e1002417. 
154. Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and 
quantification of rare mutations with massively parallel sequencing. Proc Natl 
Acad Sci U S A 2011,108:9530-9535. 
155. Fu GK, Hu J, Wang PH, Fodor SP. Counting individual DNA molecules by the 
stochastic attachment of diverse labels. Proc Natl Acad Sci U S A 
2011,108:9026-9031. 
156. Jabara CB, Jones CD, Roach J, Anderson JA, Swanstrom R. Accurate sampling 
and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc Natl 
Acad Sci U S A 2011,108:20166-20171. 
157. Huse SM, Huber JA, Morrison HG, Sogin ML, Welch DM. Accuracy and 
quality of massively parallel DNA pyrosequencing. Genome Biol 2007,8:R143. 
   47 
158. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and 
high throughput. Nucleic Acids Res 2004,32:1792-1797. 
159. Posada D. jModelTest: phylogenetic model averaging. Mol Biol Evol 
2008,25:1253-1256. 
160. Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. New 
algorithms and methods to estimate maximum-likelihood phylogenies: 
assessing the performance of PhyML 3.0. Syst Biol 2010,59:307-321. 
161. Guindon S. Bayesian estimation of divergence times from large sequence 
alignments. Mol Biol Evol 2010,27:1768-1781. 
162. Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, et al. 
Primer3--new capabilities and interfaces. Nucleic Acids Res 2012,40:e115. 
163. Vallone PM, Butler JM. AutoDimer: a screening tool for primer-dimer and 
hairpin structures. Biotechniques 2004,37:226-231. 
164. Kalendar R, Lee D, Schulman AH. Java web tools for PCR, in silico PCR, and 
oligonucleotide assembly and analysis. Genomics 2011,98:137-144. 
165. Giegerich R, Meyer F, Schleiermacher C. GeneFisher--software support for the 
detection of postulated genes. Proc Int Conf Intell Syst Mol Biol 1996,4:68-77. 
166. Fredslund J, Madsen LH, Hougaard BK, Nielsen AM, Bertioli D, Sandal N, et 
al. A general pipeline for the development of anchor markers for comparative 
genomics in plants. BMC Genomics 2006,7:207. 
167. Weckx S, De Rijk P, Van Broeckhoven C, Del-Favero J. SNPbox: a modular 
software package for large-scale primer design. Bioinformatics 2005,21:385-
387. 
168. Rouillard JM, Zuker M, Gulari E. OligoArray 2.0: design of oligonucleotide 
probes for DNA microarrays using a thermodynamic approach. Nucleic Acids 
Res 2003,31:3057-3062. 
169. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist 
programmers. Methods Mol Biol 2000,132:365-386. 
170. Allawi HT, SantaLucia J, Jr. Nearest neighbor thermodynamic parameters for 
internal G.A mismatches in DNA. Biochemistry 1998,37:2170-2179. 
171. SantaLucia J, Jr., Allawi HT, Seneviratne PA. Improved nearest-neighbor 
parameters for predicting DNA duplex stability. Biochemistry 1996,35:3555-
3562. 
172. Varghese V, Shahriar R, Rhee SY, Liu T, Simen BB, Egholm M, et al. 
Minority variants associated with transmitted and acquired HIV-1 
nonnucleoside reverse transcriptase inhibitor resistance: implications for the use 
of second-generation nonnucleoside reverse transcriptase inhibitors. J Acquir 
Immune Defic Syndr 2009,52:309-315. 
173. Palmer S, Boltz V, Martinson N, Maldarelli F, Gray G, McIntyre J, et al. 
Persistence of nevirapine-resistant HIV-1 in women after single-dose 
nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc 
Natl Acad Sci U S A 2006,103:7094-7099. 
174. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW. Characterization 
of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug 
resistance. Genome Res 2007,17:1195-1201. 
175. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, et al. 
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based 
antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 
2011,305:1327-1335. 
176. Liang B, Luo M, Scott-Herridge J, Semeniuk C, Mendoza M, Capina R, et al. A 
comparison of parallel pyrosequencing and sanger clone-based sequencing and 
 48 
its impact on the characterization of the genetic diversity of HIV-1. PLoS One 
2011,6:e26745. 
177. Di Giallonardo F, Zagordi O, Duport Y, Leemann C, Joos B, Kunzli-
Gontarczyk M, et al. Next-generation sequencing of HIV-1 RNA genomes: 
determination of error rates and minimizing artificial recombination. PLoS One 
2013,8:e74249. 
178. Gilles A, Meglecz E, Pech N, Ferreira S, Malausa T, Martin JF. Accuracy and 
quality assessment of 454 GS-FLX Titanium pyrosequencing. BMC Genomics 
2011,12:245. 
179. Zagordi O, Klein R, Daumer M, Beerenwinkel N. Error correction of next-
generation sequencing data and reliable estimation of HIV quasispecies. 
Nucleic Acids Res 2010,38:7400-7409. 
180. Fang G, Zhu G, Burger H, Keithly JS, Weiser B. Minimizing DNA 
recombination during long RT-PCR. J Virol Methods 1998,76:139-148. 
181. Eckert KA, Kunkel TA. DNA polymerase fidelity and the polymerase chain 
reaction. PCR Methods Appl 1991,1:17-24. 
182. Wu JY, Jiang XT, Jiang YX, Lu SY, Zou F, Zhou HW. Effects of polymerase, 
template dilution and cycle number on PCR based 16 S rRNA diversity analysis 
using the deep sequencing method. BMC Microbiol 2010,10:255. 
183. Shao W, Boltz VF, Spindler JE, Kearney MF, Maldarelli F, Mellors JW, et al. 
Analysis of 454 sequencing error rate, error sources, and artifact recombination 
for detection of Low-frequency drug resistance mutations in HIV-1 DNA. 
Retrovirology 2013,10:18. 
184. Shiroguchi K, Jia TZ, Sims PA, Xie XS. Digital RNA sequencing minimizes 
sequence-dependent bias and amplification noise with optimized single-
molecule barcodes. Proc Natl Acad Sci U S A 2012,109:1347-1352. 
185. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, Craig C, et al. Minority HIV-
1 drug resistance mutations are present in antiretroviral treatment-naive 
populations and associate with reduced treatment efficacy. PLoS Med 
2008,5:e158. 
186. Metzner KJ, Giulieri SG, Knoepfel SA, Rauch P, Burgisser P, Yerly S, et al. 
Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure 
in treatment-naive and -adherent patients. Clin Infect Dis 2009,48:239-247. 
187. Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, Baxter JD, et 
al. Low-abundance drug-resistant viral variants in chronically HIV-infected, 
antiretroviral treatment-naive patients significantly impact treatment outcomes. 
J Infect Dis 2009,199:693-701. 
188. Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 
2003,362:2002-2011. 
 
 
